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QUINOLONE	MECHANISM	OF	ACTION:	
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ABSTRACT		 Antibiotics	are	a	foundation	of	modern	medicine,	helping	to	save	millions	of	lives	 since	 their	 discovery	 in	 1928.	 But	 the	 improper	 and	 excessive	 use	 of	 these	drugs	 over	 the	 last	 few	 decades	 has	 led	 to	 an	 alarming	 increase	 in	 antimicrobial	resistance;	 coupled	 with	 the	 recent	 decrease	 in	 antibiotic	 discovery,	 it	 is	 widely	thought	 that	 we	 are	 approaching	 a	 post-antibiotic	 era.	 A	 less	 well-understood	problem	is	that	of	drug	tolerance.	Even	at	high	doses,	antibiotics	often	cannot	kill	all	the	 bacteria	 in	 an	 infection	 because	 of	 cells	 that	 are	 able	 to	 tolerate	 antibiotic	treatment.	 	 Evidence	 points	 to	 drug-tolerant	 cells,	 also	 called	 persisters,	 to	 be	 a	major	cause	of	treatment	failure	and	chronic	and	recurring	infections		
	 It	is	imperative	that	we	develop	insight	and	methods	to	prevent	the	spread	of	antimicrobial	 resistance	 and	 combat	 antimicrobial	 tolerance.	 One	 key	 effort	 is	characterizing	bacterial	responses	to	antibiotic	drug	treatment	to	generate	a	more	comprehensive	 understanding	 of	 the	 factors	 that	 contribute	 to	 cell	 death	 and	 to	elucidate	potential	 targets	 for	new	therapies.	Quinolones	are	an	important	class	of	antibiotics	 that	 target	 DNA	 replication.	 They	 bind	 to	 topoisomerase	 II	 and	 IV,	
		 viii	
leading	to	eventual	DNA	fragmentation	and	death.	However,	the	precise	mechanism	by	which	 they	work	 is	not	well	understood.	Because	 they	 inhibit	DNA	replication,	quinolones	 lead	 to	 up-regulation	 of	 the	 SOS	 response,	which	 allows	 for	 increased	mutagenesis	 and	 the	potential	 for	 increased	antimicrobial	 resistance,	 thus	making	quinolones	an	interesting	class	of	antibiotics	to	study.	Although	quinolones	are	one	of	the	most	effective	classes	of	antibiotics,	there	are	many	conditions	in	which	they	do	 not	 kill,	 such	 as	 in	 stationary-phase	 cultures.	 Understanding	 the	 mechanism	behind	 quinolone	 killing,	 quinolone-induced	 mutagenesis	 and	 tolerance	 to	quinolones	is	important	to	improve	quinolone	efficacy.	
	 Here	 I	 have	 presented	 my	 work	 on	 understanding	 quinolones:	 sensitivity,	mutagenesis	and	tolerance.	In	understanding	quinolone	sensitivity,	I	 focus	on	DNA	repair	 and	 its	 involvement	 in	 quinolone-mediated	 death.	 I	 then	 probe	 the	 field	 of	stress-induced	 mutagenesis	 by	 quinolones,	 uncovering	 phenotypes	 of	 dose-dependent	mutagenesis	that	have	previously	been	uncharacterized.	Finally,	 I	 focus	on	 drug	 tolerance	 and	 how	 density-dependent	 tolerance	 to	 quinolones	 can	 be	reversed	 by	 up-regulating	 cellular	 respiration	 through	 the	 addition	 of	 a	 carbon	source	and	electron	acceptor.		 	 	
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CHAPTER	ONE:	INTRODUCTION	
	
1.1	The	Antibiotic	Problem		 Antibiotics	have	been	a	foundation	of	modern	medicine	since	their	discovery	in	 1928.	 However,	 resistance	 to	 antibiotics	 has	 been	 a	 rising	 problem	 making	antibiotic	 treatment	 ineffective	and	bringing	us	closer	 to	a	post-antibiotic	era.	The	use	(in	some	cases	misuse)	of	antibiotics	has	led	to	the	rise	and	spread	of	bacteria	expressing	resistance	 factors,	making	 infections	harder	 to	 treat.	This	war	between	humans	 and	 pathogens	 has	 led	 to	 multidrug	 resistance	 ESKAPE	 organisms	(Enterococcus,	 Staphylococcus	 aureus,	 Klebsiella	 species,	 Acinetobacter	 baumannii,	
Pseudomonas	aeruginosa,	Enterobacter)(Boucher,	Talbot	 et	 al.	 2009).	Resistance	 is	thought	 to	 occur	 through	 several	 mechanisms,	 including	 target	 modification,	hindered	drug	uptake	and	drug	obliteration	(Lewis	2016).		 A	less	well-understood	problem	is	that	of	drug	tolerance.	Even	at	high	doses,	antibiotics	often	cannot	kill	all	the	bacteria	in	an	infection	because	of	cells,	which	are	able	 to	 tolerate	 antibiotic	 treatment.	 	 Evidence	 points	 to	 drug-tolerant	 cells,	 also	called	persisters,	to	be	a	major	cause	of	treatment	failure	and	chronic	and	recurring	infections	 (Lewis	2010).	Although	 it	 is	difficult	 to	study	persisters	 in	vivo	because	there	 are	 so	 few	 of	 them,	 there	 is	 evidence	 that	 persister	 cells	 lead	 to	 chronic	infections.	 Mulcahy	 et	 al.	 (Mulcahy,	 Burns	 et	 al.	 2010)	 found	 an	 increase	 in	 high	persistence	 mutations	 (hip)	 in	 10	 out	 of	 14	 patients	 with	 chronic	 cystic	 fibrosis,	caused	by	a	P.	aeruginosa	infection.		
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	 Recently	there	has	also	been	accumulating	evidence	that	drug-tolerant	cells	can	 increase	 the	 potential	 of	 an	 infection	 to	 develop	 resistance,	 making	 this	phenomenon	even	more	crucial	to	understand	(Cohen,	Lobritz	et	al.	2013).	
	
1.2	Approaches	to	circumvent	antimicrobial	resistance	and	tolerance		 Researchers	have	resorted	to	a	variety	of	approaches	to	deal	with	antibiotic	resistance	 and	 tolerance.	 One	 important	 undertaking	 has	 been	 the	 attempt	 to	discover	new	antibiotics.	Researchers	have	tried	to	discover	new	antibiotics	through	high-throughput	methods,	through	the	chemical	alteration	of	previously	discovered	antibiotics,	and	more	recently	through	synthetic	biology.				 Surveys	 of	 sequenced	 bacterial	 genomes	 have	 shown	 that	 the	 majority	 of	clusters	 within	 the	 genome	 are	 not	 expressed	 during	 laboratory	 culturing.	 Thus,	there	 is	 a	 huge	 potential	 for	 untapped	 products	 that	 could	 be	 used	 as	 antibiotics	(Butler,	 Blaskovich	 et	 al.	 2016).	 Genome	 mining	 has	 been	 used	 to	 discover	 new	antibiotics	 such	 as	 haloduracin	 (McClerren,	 Cooper	 et	 al.	 2006).	 This	method	 has	been	 advanced	 to	 a	 method	 called	 metagenome	 mining	 to	 search	 for	 antibiotics	from	 organisms	 that	 cannot	 be	 cultured	 in	 the	 laboratory	 by	 extracting	 genomic	data	directly	from	an	environmental	sample.	Researchers	have	also	developed	new	methods	 to	culture	previously	un-cultureable	bacteria	 to	discover	new	antibiotics.	Notably,	 Nichols	 et	 al.	 developed	 an	 iChip	 to	 culture	 soil	 bacteria.	 The	 chip	 is	 a	multichannel	device	which,	when	dipped	into	a	soil	culture,	captures	approximately	one	bacteria	per	channel.	The	 iChip	 is	 then	 incubated	 in	soil	 to	allow	 for	bacterial	
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growth	 (Nichols,	 Cahoon	et	 al.	 2010).	 Ling	 et	 al.	 used	 the	 iChip	 to	discover	 a	new	antibiotic	called	teixobactin,	which	inhibits	cell	wall	synthesis	(Ling,	Schneider	et	al.	2015).		 Naturally	 discovered	 antibiotics	 have	 been	 altered	 using	 chemical	 and	enzymatic	 approaches	 to	 produce	 drugs	 that	 are	 more	 efficacious.	 For	 example,	researchers	were	able	 to	alter	vancomycin,	a	naturally	derived	antibiotic	 that	was	approved	 by	 the	 FDA	 in	 1958	 (Butler,	 Hansford	 et	 al.	 2014).	 Because	 of	 the	 ease	with	which	vancomycin’s	C-terminal	can	be	modified,	three	semi-synthetic	forms	of	vancomycin	 were	 approved:	 telavancin	 (Leadbetter,	 Adams	 et	 al.	 2004),	dalbavancin	 (Leadbetter,	 Adams	 et	 al.	 2004)	 and	 oritavancin	 (Bouza	 and	 Burillo	2010).		 Because	the	rate	of	discovery	of	new	antibiotics	has	been	much	slower	than	the	development	of	resistance,	researchers	have	attempted	to	use	synthetic	biology	to	kill	bacteria.	One	example	is	the	use	of	riboswitches,	RNA	aptamers	that	change	conformation	 to	 express	 genes	 when	 they	 bind	 to	 specific	 targets.	 By	 finding	repressors	 for	 guanine	 riboswitches	 which	 lead	 to	 repression	 of	 purine	biosynthesis,	Kim	et	al.	found	that	they	could	inhibit	B.	subtilis	growth	(Kim,	Blount	et	 al.	 2009).	 In	 another	 example,	 Krom	 et	 al.	 engineered	 bacterial	 phagemids	 to	release	 antimicrobial	 peptides	 (AMPs)	 and	 protein	 toxins	 to	 induce	 cell	 death	(Krom,	Bhargava	et	al.	2015).			 Another	approach	to	solving	the	antibiotic	problem	is	by	gaining	insight	into	the	 antibiotic	 mechanism	 of	 killing	 to	 pinpoint	 targets	 for	 new	 antibiotics	 or	
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adjuvant	 therapies.	 Originally,	 antibiotics	 were	 classified	 primarily	 by	 their	 drug-target	interactions.	Three	classes	of	drugs	which	I	have	focused	on	in	this	thesis	are	quinolones,	 which	 target	 the	 DNA,	 beta-lactams,	 which	 target	 the	 cell	 wall,	 and	amino-glycosides,	 which	 target	 ribosomes	 (Walsh	 2003).	 The	 Collins	 lab	 has	hypothesized	 that	 drug-target	 interactions	 lead	 to	 downstream	 alterations	within	the	 cell,	 which	 lead	 to	 cell	 death.	 As	 antibacterial	 resistance	 becomes	 a	 bigger	problem,	 it	 is	 important	 to	 study	 and	 understand	 downstream	 pathways,	 which	could	 be	 resisting	 antibiotic	 treatment.	 The	 Collins	 lab	 has	 taken	 systems	 biology	approach	to	understand	how	cells	are	altered	at	a	systemic	level	when	treated	with	antibiotics.		 In	2007,	the	Collins	lab	found	that	bactericidal	antibiotics,	antibiotics	that	kill	cells,	 share	 a	 downstream	 pathway	 of	 radical	 oxygen	 species	 (ROS)	 production	before	 cell	 death.	 Through	 gene	 expression	 microarrays,	 they	 found	 that	 ROS	production	correlates	with	an	up-regulation	in	the	TCA	cycle	and	depletion	of	NADH	(Kohanski,	 Dwyer	 et	 al.	 2007).	 This	work	 led	 to	methods	 for	 enhancing	 bacterial	efficacy	 by	 up-regulating	 the	 TCA	 cycle.	 Specifically,	 researchers	 were	 able	 to	potentiate	 stationary	 phase	 cells	 to	 aminoglycosides	 by	 promoting	 TCA	 cycle	activity	 and	 increasing	 the	 proton	 motive	 force	 (PMF)	 (Allison,	 Brynildsen	 et	 al.	2011,	Meylan,	Porter	et	al.	2017).			 The	systems	biology	approach	has	also	been	used	to	study	other	aspects	of	antibiotic	 treatment.	 Modi	 et	 al.	 explored	 how	 antibiotic	 treatment	 can	 affect	 the	phageome	 by	 sequencing	 murine	 faecal	 phage	 populations	 after	 antibiotic	
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perturbations.	She	found	that	exposure	to	antibiotics	led	to	an	enrichment	in	phage-encoded	 genes	 that	 confer	 resistance	 (Modi,	 Lee	 et	 al.	 2013).	 Belenky	 et	 al.	 used	metabolomic	 profiling	 to	 find	 that	 antibiotics	 lead	 to	 an	 up-regulation	 in	 central	carbon	metabolites,	breakdown	of	 the	nucleotide	pool,	 reduced	 lipid	 levels	and	an	elevated	 redox	 state	 (Belenky,	 Ye	 et	 al.	 2015).	 Finally,	 Cohen	 et	 al.	 used	 single-molecule	 real-time	 sequencing	 (SMRT)	 to	 understand	 what	 role	 the	 GATC	methylome	plays	in	antibiotic	stress	response.	She	found	that	the	GATC	methylome	provides	 structural	 support	 to	 the	 DNA,	 without	 which	 antibiotic	 efficacy	 is	enhanced	(Cohen,	Ross	et	al.	2016).			 In	this	way,	using	a	systems	biology	approach	to	understand	how	antibiotics	work	has	 been	beneficial	 in	 revealing	downstream	pathways	 for	 antibiotic	 action,	and	suggesting	new	targets	to	improve	antibiotic	efficacy.	However,	because	of	the	complexity	of	 antibiotics,	 a	 systems	 level	approach	can	only	go	 so	 far	 in	 revealing	the	 specific	 details	 of	 the	 pathways	 and	 pinpointing	 specific	 targets.	 In	my	PhD,	 I	have	 used	 a	 bottom-up	 approach	 to	 study	 antibiotic	 killing	 in	more	 detail.	 I	 have	searched	for	phenotypes	unrelated	to	the	drug-target	interaction	and	attempted	to	perturb	 these	 phenotypes	 to	 gain	 a	 deeper	 understanding	 of	 the	 secondary	mechanisms	by	which	antibiotics	kill	bacteria.	
	
1.3	Quinolones’	mechanism	of	action		 Quinolones	are	a	class	of	antibiotics	that	target	the	DNA.	The	first	quinolone	to	 be	 clinically	 approved	 was	 nalidixic	 acid,	 in	 1967.	 Since	 then,	 many	 new	
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quinolones	have	been	made	based	on	the	4-oxo-1,4-dihydroquinolone	skeleton.	The	first	generation	of	quinolones,	including	nalidixic	acid	and	oxolinic	acid	are	used	for	Gram-negative	 bacteria;	 new	 generations	 of	 quinolones	 have	 been	 developed	 to	treat	 a	 broader	 range	 of	 species	 including	 some	 Gram-positive	 organisms	 and	anaerobic	bacteria	(Cheng,	Hao	et	al.	2013).			 All	 quinolones	 target	 topoisomerase	 II,	 also	 called	 DNA	 gyrase,	 while	 only	second-generation	and	more	 recent	quinolones	 target	 topoisomerase	 IV	 (topo	 IV).	By	 binding	 to	 the	 subunit	 A	 of	 DNA	 gyrase,	 quinolones	 inhibit	 the	 ability	 of	 DNA	gyrase	 to	 ligate	 DNA	 strands	 after	 cleavage.	 In	 E.	 coli	 and	 other	 Gram-negative	bacteria,	topo	IV	inhibition	is	secondary	to	gyrase	inhibition	and	strains	resistant	to	topo	IV	are	still	susceptible	to	quinolones	(Soussy,	Wolfson	et	al.	1993,	Khodursky,	Zechiedrich	 et	 al.	 1995,	 Chen,	 Malik	 et	 al.	 1996,	 Heisig	 1996).	 In	 Gram-positive	bacteria	such	as	S.	aureus	and	P.	neumoniae	however,	topo	IV	is	the	primary	target	for	 ciprofloxacin	 (Orphanides	 and	 Maxwell	 1994,	 Blanche,	 Cameron	 et	 al.	 1996,	Munoz	and	De	La	Campa	1996,	Pan,	Ambler	et	al.	1996).			 When	quinolones	bind	to	gyrase,	 they	form	a	reversible	quinolone-enzyme-DNA	complex,	which	contains	a	double	stranded	break	within	it	(Gellert,	Mizuuchi	et	al.	 1977,	 Sugino,	 Peebles	 et	 al.	 1977).	 These	 double-stranded	 breaks	 are	 revealed	when	 cells	 are	 treated	 with	 sodium	 dodecyl	 sulfate	 (SDS).	 	 The	 formation	 of	quinolone-enzyme-DNA	complexes	leads	to	rapid	replication	arrest	in	E.	coli	(Goss,	Deitz	 et	 al.	 1964).	 This	 arrest	 is	 50–100	 times	 slower	 through	 topo	 IV	 binding	(Khodursky,	 Zechiedrich	 et	 al.	 1995),	 likely	 because	 topo	 IV	 activity	 is	 behind	
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replication	forks	while	gyrase	activity	is	ahead	of	them.	Interestingly,	the	formation	of	 cleaved	 complexes,	 replication	 and	 growth	 inhibition	 are	 all	 reversible	phenotypes;	 thus,	 they	 are	 not	 directly	 correlated	 with	 death.	 Secondary	mechanisms	must	be	present	for	quinolones	to	kill	cells.		 A	 secondary	 mechanism	 that	 has	 been	 implicated	 in	 cell	 death	 is	 the	production	of	double-stranded	breaks	(DSBs)	that	fragment	the	DNA	(Chen,	Malik	et	al.	 1996).	 Some	 hypothesize	 that	 these	 DSBs	 are	 formed	 through	 the	 collision	 of	blocked	 replication	 forks	 (Pohlhaus	 and	 Kreuzer	 2005)	 or	 through	 the	 release	 of	DSBs	 from	 the	 cleaved	 complexes.	 Quinolones’	 lethal	 activity	 is	 inhibited	 or	impaired	 by	 chloramphenicol,	 indicating	 a	 protein-synthesis	 dependent	 and	independent	pathway	 for	quinolone	 lethality.	Quinolone	activity	 is	also	dependent	on	anaerobiosis.	There	is	evidence	that	quinolones	require	the	production	of	ROS	to	kill	 cells	 (Kohanski,	 Dwyer	 et	 al.	 2007).	 Foti	 et	 al.	 have	 described	 a	 downstream	mechanism	 in	 which	 ROS	 can	 damage	 nucleotides	 and	 result	 in	 repair	 enzyme	mediated	 cell	 fragmentation	 (Foti,	 Devadoss	 et	 al.	 2012).	 The	 link	 between	quinolone	 action	 and	 DNA	 fragmentation	 mediated	 death	 is	 thus	 not	 clearly	understood,	though	there	are	many	pathways	that	have	been	shown.		 Quinolone	 action	 results	 in	 the	 activation	 of	 the	 SOS	 response,	 the	 cell’s	response	 to	 DNA	 damage,	 which	 is	 regulated	 by	 30	 genes	 controlled	 by	 the	 lexA	repressor.	 The	 lexA	 repressor	 is	 degraded	when	 RecA	 binds	 to	 free	 ssDNA	 ends,	resulting	in	the	expression	of	the	SOS	genes	(Khil	and	Camerini-Otero	2002).	These	genes	 are	 involved	 in	 DNA	 repair,	 recombination,	 filamentation	 and	 mutagenesis	
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(Walker	1984,	Kelley	2006).	The	action	of	DNA	repair	genes	under	quinolone	stress	is	 not	 well	 understood,	 but	 there	 is	 literature	 showing	 both	 protective	 and	sensitizing	 effects	 from	 these	 enzymes.	 Because	 of	 the	 rise	 of	 antimicrobial	resistance,	it	is	important	to	better	understand	the	relationship	between	quinolone	damage	that	leads	to	death	and	damage	that	leads	to	increased	mutagenesis.			 There	are	many	conditions	in	which	quinolones	are	unable	to	kill	bacteria.	As	previously	mentioned,	quinolones	cannot	kill	as	effectively	when	there	is	no	protein	synthesis,	such	as	in	bacteria	treated	with	chloramphenicol	(Malik,	Zhao	et	al.	2006),	and	 in	 anaerobic	 conditions	 (Malik,	 Hussain	 et	 al.	 2007).	 Researchers	 have	 also	found	 that	 ciprofloxacin	 treatment	 promotes	 the	 expression	 of	 toxin/antitoxin	genes,	which	are	thought	to	be	required	for	persister	 formation	(Dorr,	Lewis	et	al.	2009).	 Finally,	 a	 growth-dependent	 killing	 phenotype	 for	 quinolones	 has	 been	described	 (Zeiler	 1985).	 To	 make	 quinolone	 more	 effective	 to	 treatment,	 it	 is	imperative	 that	we	understand	why	quinolones	 are	 lethal	 in	 some	 conditions	 and	not	in	others,	and	how	we	can	increase	lethality.	
	
1.4	Thesis	outline		 I	have	broken	my	thesis	into	three	chapters,	all	studying	a	different	aspect	of	quinolone	 efficacy:	 sensitivity,	mutagenesis	 and	 tolerance.	 In	 Chapter	 2,	 I	 ask	 the	question,	what	 role	does	DNA	 repair	 play	 in	 antibiotic	 killing?	To	 this	 end,	 I	 have	used	genetic	mutants	and	microscopic	approaches	to	reveal	the	encompassing	role	that	DNA	repair	enzymes	play	in	quinolone	sensitivity.	In	Chapter	3,	I	probe	the	field	
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of	 stress-induced	 mutagenesis	 by	 quinolones,	 uncovering	 phenotypes	 of	 dose-dependent	 mutagenesis	 that	 have	 previously	 been	 uncharacterized.	 Finally,	 in	Chapter	 4,	 I	 focus	 on	 drug	 tolerance	 and	 how	 density-dependent	 tolerance	 to	quinolones	 can	 be	 reversed	 by	 up-regulating	 cellular	 respiration	 through	 the	addition	of	a	carbon	source	and	electron	acceptor.		  
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CHAPTER	TWO:	DNA	REPAIR	IN	QUINOLONE	SENSITIVITY	
	
2.1	INTRODUCTION		 Quinolones’	 primary	 targets	 are	 topoisomerase	 II	 and	 IV;	 they	 reversibly	bind	to	these	targets	and	form	stable	complexes	(Cheng,	Hao	et	al.	2013).	Quinolone	action	 also	 leads	 to	 DSB	 formation	 and	 DNA	 fragmentation,	 phenotypes	 that	 are	linked	 to	quinolone-mediated	death.	 It	 is	not	well	 accepted	how	quinolones	 cause	the	 formation	 of	 DSBs.	 One	 mechanism,	 proposed	 by	 Foti	 et	 al.,	 shows	 that	 a	breakdown	 in	 DNA	 damage	 repair	 can	 lead	 to	 DSBs	 (Foti,	 Devadoss	 et	 al.	 2012).	They	found	that	by	removing	mutY	and	mutM,	DNA	glycosylases	that	repair	8-oxo-guanine,	 they	 could	 improve	 cell	 survival	 after	 antibiotic	 treatment.	 They	hypothesized	that	the	cutting-action	of	these	enzymes	produced	pseudo-DSBs	when	damaged	bases	were	 in	close	proximity,	 thus	 leading	 to	cell	death.	My	goal	 in	 this	chapter	is	to	expand	the	understanding	of	how	DNA	repair	can	contribute	to	death	by	quinolones.		
2.1.2	ROS	and	its	contribution	to	DNA	damage	
	 ROS	 was	 first	 mentioned	 in	 relation	 to	 antibiotic	 lethality	 in	 1990	 when	Greenberg	et	al.	found	a	relation	between	the	soxR	regulon	and	antibiotic	resistance	(Greenberg,	Monach	et	al.	1990).	The	first	direct	evidence	to	support	the	theory	that	antibiotics	induce	ROS	to	kill	cells	came	over	a	decade	later	when	scientists	showed	
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that	beta-	carotene,	an	antioxidant,	prevented	mutagenesis	by	quinolone	antibiotics	(Arriaga-Alba,	Rivera-Sanchez	et	al.	2000).			 The	Collins	lab	took	a	systems	level	approach	to	study	how	antibiotics	affect	various	 pathways	 in	 the	 cell.	 In	 2007,	 Dwyer	 et	 al.	 found	 through	 microarray	analysis	 that	 gyrase	 inhibition	 results	 in	 an	 up-regulation	 of	 oxidative	 stress,	hypothesizing	 that	 iron	mis-regulation	 leads	 to	 the	 formation	of	hydroxyl	 radicals	(Dwyer,	 Kohanski	 et	 al.	 2007).	 Kohanski	 et	 al.	 later	 showed,	 through	 the	 use	 of	hydroxyphenyl	 fluorescein	 (HPF)	 —	 a	 dye	 for	 hydroxyl	 radicals	 —	 and	 an	 iron	chelator	—	a	chemical	that	reduces	the	production	of	hydroxyl	radicals	from	ferrous	iron	 —	 that	 other	 bactericidal	 antibiotics,	 specifically	 beta-lactams	 and	aminoglycosides,	also	induce	ROS.			 Foti	et	al.	laid	out	a	possible	mechanism	for	how	oxidative	stress	can	lead	to	DNA	damage	and	death	 (Foti,	Devadoss	et	al.	2012).	They	showed	 that	antibiotics	lead	 to	 an	 increase	 in	oxidized	guanine	 in	 the	DNA	because	of	 oxidative	 stress.	 In	general,	oxidized	guanine	is	a	mutagenic	lesion	that	leads	to	a	point	mutation	in	the	DNA	 when	 left	 unrepaired.	 However,	 under	 antibiotic	 stress	 this	 lesion	 become	genotoxic,	 leading	 to	 cell	 death.	 Foti	 et	 al.	 described	 that	 cell	 death	 by	 oxidized	lesions	 is	due	 to	a	breakdown	 in	DNA	repair.	 Specifically,	when	Foti	 et	 al.	 deleted	mutY	and	mutM,	 enzymes	 involved	 in	 removing	oxidized	 guanine	 from	DNA,	 they	found	that	cells	survived	better.	They	proposed	that	the	action	of	removing	oxidized	guanine	 would	 result	 in	 lesions	 that	 mimicked	 DSBs,	 which	 are	 genotoxic,	 thus	leading	to	death.		
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	 There	 is	 also	 evidence	 that	 ROS	 affects	 DNA	 replication.	 Charbon	 et	 al.	showed	 that	 hyperinitiation	 of	 replication	 in	 an	 hda	 mutant,	 resulting	 in	 an	increased	 origin:terminus	 ratio,	 can	 be	 prevented	 in	 anaerobic	 environments	(Charbon,	 Bjorn	 et	 al.	 2014).	 They	 concluded	 that	 death	 by	 hyperinitiation	 in	aerobic	environments	is	due	to	replication	forks	approaching	single	stranded	breaks	(SSBs)	 where	 oxidized	 bases	 have	 been	 removed,	 resulting	 in	 double	 stranded	breaks	(DSBs).	In	anaerobic	conditions	there	is	little	damage	and	thus	replication	is	completed	without	issues.			 The	 significant	 research	 relating	 ROS	 to	 DNA	 damage	 brings	 about	 many	interesting	 questions.	 Do	 all	 DNA	 repair	mechanisms	 breakdown	 under	 antibiotic	stress	leading	to	cell	death?	What	specific	damage	do	repair	mechanisms	cause?	In	this	 chapter	 I	 have	 laid	 out	 data	 exploring	 the	 effects	 of	 DNA	 repair	 on	 death	 by	quinolones	and	antibiotics	un-related	to	DNA	damage.		 DNA	 repair	 is	 crucial	 in	 maintaining	 DNA	 fidelity.	 However,	 it	 has	 been	shown	 that	under	antibiotic	 stress,	 some	DNA	repair	 enzymes	enhance	 cell	death.	Bacteria	 have	 many	 DNA	 repair	 pathways	 such	 as	 base	 excision	 repair	 (BER),	nucleotide	 excision	 repair	 (NER),	 mismatch	 repair	 (MMR),	 and	 homologous	recombination	 (HR).	 Using	 P1	 transduction,	 we	 have	 made	 single	 and	 double	mutants	of	enzymes	in	these	pathways	in	the	Escherichia	Coli	MgC1	strain.	The	first	step	 in	 understanding	 how	DNA	 damage	 repair	 affects	 death	 and	mutagenesis	 by	antibiotics	 is	 to	 characterize	 these	 mutants	 in	 DNA	 repair	 with	 and	 without	antibiotic	stress.		
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2.2	RESULTS	
2.2.1	Characterization	of	DNA	damage	after	quinolone	treatment		 In	understanding	what	role	DNA	repair	enzymes	have	on	antibiotic-induced	cell	 death,	 our	 first	 step	was	 to	 characterize	 the	 damage	 present	 after	 treatment.	Because	 of	 its	 direct	 action	 against	 the	DNA,	we	 first	 studied	 the	DNA	damage	 of	cells	treated	with	nalidixic	acid,	a	first-generation	quinolone.				 DNA	glycosylases	are	DNA	repair	enzymes	that	remove	mutated	bases	such	as	8-oxo	guanine,	xanthine,	hypoxanthine	and	inosines	to	name	a	few.	Specific	DNA	glycosylases	are	in	charge	of	removing	specific	types	of	damage.	For	example,	mutM	removes	8-oxo-guanine	and	mutY	removes	‘A’	paired	to	8-oxo-guanine.	Nei	and	nth	are	glycosylases	which	remove	other	oxidized	bases	such	as	pyrimidine	dimers,	and	nfi	excises	deaminated	bases	such	as	xanthine	and	hypoxanthine.	To	give	us	insight	into	which	 damaged	 bases	 are	 being	 incorporated	 into	 the	 DNA	 during	 antibiotic	stress,	we	tested	mutants	for	these	DNA	damage	repair	enzymes	with	and	without	antibiotic	treatment.			 Because	 of	 the	 literature	 implicating	 ROS	 in	 antibiotic-induced	 death	(Kohanski,	Dwyer	et	al.	2007),	we	first	 tested	mutants	that	repair	bases	related	to	oxidized	 damage.	 We	 found	 that	 removing	 mutY	 and	 mutM	 resulted	 in	 a	 small	increase	in	cell	survival	(Figure	2.1a).	The	phenotype	was	not	as	strong	as	what	was	shown	by	Foti	et	al.	 for	norfloxacin	(Foti,	Devadoss	et	al.	2012),	but	by	2	hours	of	treatment,	 a	 slight	 advantage	 for	 the	 mutant	 is	 clear.	 Foti	 et	 al.	 explained	 this	
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mutY/mutM	 phenotype	 by	 describing	 a	 mechanism	 in	 which	 the	 removal	 of	oxidized	guanine	and	the	mismatched	‘A’	by	these	enzymes	results	in	closely	spaced	nicks	in	the	DNA,	which	are	toxic	to	cells	just	as	DSBs	are.		 We	next	found	that	removing	nei	and	nth	lead	to	a	slightly	greater	increase	in	survival.	 This	 led	 us	 to	 hypothesize	 first	 that	 other	 oxidized	 lesions	 such	 as	pyrimidine	dimers	play	a	role	in	antibiotic	death,	and	second	that	nei	and	nth,	just	as	mutY	and	mutM,	cause	genotoxic	 lesions	when	they	remove	these	oxidized	lesions	from	 the	DNA	 (Figure	2.1b).	 This	 data	 expands	 the	 current	 understanding	 that	 8-oxo-guanine	is	being	incorporated	into	the	DNA	to	include	other	oxidized	bases	and	supports	 the	 hypothesis	 that	 ROS	 is	 leading	 to	 a	 variety	 of	 oxidized	 bases	 in	 the	DNA.			
		
15	
					 	
Figure	2.1:	Glycosylases	involved	in	repair	of	oxidized	bases	sensitize	cells	to	
antibiotics.	We	treated	cells	with	a	range	of	concentrations	of	nalidixic	acid	at	60	minutes,	90	minutes	and	2	hours.	a)	We	saw	a	slight	increase	in	survival	for	mutants	of	mutY/mutM	(green)	compared	to	the	wildtype	(black)	by	2	hours.	b)	We	saw	an	increase	in	survival	for	mutants	of	nei/nth	(red)	compared	to	wildtype	(black)	by	2	hours.			 To	 confirm	 that	 oxidized	 bases	 are	 playing	 a	 role	 after	 nalidixic	 acid	treatment,	we	made	a	quadruple	knockout	of	mutY,	mutM,	nei	and	nth.	We	treated	
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this	mutant	with	100	μg/mL	nalidixic	acid	and	found	that	the	mutant	survives	10-fold	more	than	the	wildtype	(Figure	2.2).	
	
Figure	2.2:	Role	of	oxidative	damage	repair	on	nalidixic	acid	stress.	We	treated	cells	 with	 nalidixic	 acid	 (100	 ug/mL)	 for	 up	 to	 2	 hours.	 We	 found	 that	 a)	mutY/mutM	 (green)	 is	 more	 tolerant	 to	 nalidixic	 acid	 than	 wildtype	 (black),	 b)	nei/nth	 (red)	 is	 just	 slightly	more	 tolerant	 to	nalidixic	 acid	 than	wildtype	 (black),	and	 c)	 mutY/mutM/nei/nth	 (blue)	 is	 significantly	 more	 tolerant	 to	 nalidixic	 acid	than	wildtype	(black).			 We	next	tried	removing	nfi,	which	has	a	multitude	of	functions	in	DNA	repair,	one	of	which	is	to	assist	 in	the	excision	of	hypoxanthine	and	xanthine,	deaminated	adenine	and	guanine	respectively	(Kuraoka	2015).	Unlike	DNA	glycosylases,	which	are	 part	 of	 base-excision	 repair	 (BER)	 and	 nucleotide-excision	 repair	 (NER),	 nfi	participates	in	alternative	excision	repair	(AER)	by	creating	a	nick	in	the	DNA	near	damaged	bases	to	begin	repair.	
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	 Removing	 nfi	 lead	 to	 a	 strong	 increase	 in	 cell	 sensitivity	 (Figure	 2.3),	indicating	 that	 its	 action	 is	 required	 for	 cells	 resisting	 quinolone	 action.	 We	hypothesized	 that	 damaged	 bases	 recognized	 by	 nfi,	 such	 as	 xanthine	 and	hypoxanthine,	could	be	toxic	to	the	cells	and	require	nfi-mediated	repair.		
	
Figure	2.3:	The	role	of	Nfi	in	sensitivity	to	nalidixic	acid.	We	treated	cells	with	a	range	 of	 concentrations	 of	 nalidixic	 acid	 at	 60	 minutes,	 90	 minutes	 and	 2	 hours	(corresponding	to	panels	from	left	to	right).	We	saw	a	strong	increase	in	sensitivity	for	the	nfi	mutant	(purple)	compared	to	the	wildtype	(black)	by	2	hours.			 Bases	 repaired	 by	 nfi	 are	 formed	 through	 deamination	 and	 require	nitrosative	 stress.	 To	 test	 our	 hypothesis	 that	 the	 nfi	 phenotype	 is	 due	 to	deaminated	 bases	 such	 as	 xanthine	 and	 hypoxanthine,	 we	 knocked	 out	 RdgB,	 a	pyrophosphatase	 that	 hydrolyses	 xanthosine	 triphosphate,	 and	 deoxyinosine	triphosphate	among	other	non-canonical	purine	nucleotides.	 It	 thus	 functions	as	a	
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house-cleaning	 enzyme	 that	 removes	 damaged	 purines	 from	 the	 base	 pool.	 We	hypothesized	 that	 by	 knocking	 out	 RdgB	 in	 an	 nfi	 background,	 we	 would	 see	 an	increase	 in	 nfi	 sensitivity.	 However,	 we	 found	 that	 RdgB	 mutant	 has	 the	 same	phenotype	in	the	wildtype	background	and	in	the	nfi	background	(Figure	2.4a).	We	next	 tested	nitrate	 reductases	napA	and	narG	 in	 the	nfi	 background.	We	expected	that	 if	 nitrate	 reductases	 were	 not	 present,	 DNA	 damage	 from	 nitrosative	 stress	would	 also	 not	 be	 present.	 Thus,	 if	 the	 role	 of	 nfi	 is	 to	 repair	 bases	 damaged	 by	nitrosative	 stress,	 the	 nfi	 mutant	 should	 behave	 as	 napA	 and	 narG	 in	 the	 double	knockouts.	 Surprisingly,	 we	 found	 that	 napA/nfi	 survived	 1	 log	 more	 than	 the	wildtype,	while	 narG/nfi	 performed	 slightly	worse	 than	 narG.	 These	 results	were	inconclusive	 and	 a	more	 thorough	 study	 of	 the	 effects	 of	 nitrate	 and	 deaminated	bases	 on	 the	 nfi	 phenotype	 should	 be	 done	 to	 understand	 the	 function	 of	 nfi	 in	antibiotic	stress.	
	
Figure	2.4:	The	role	of	deaminated	bases	in	nfi	phenotype.	All	experiments	were	done	with	100	ug/mL	nalidixic	acid	treatment	over	time.	We	tested	double	mutants	of	nfi	with	a)	RdgB,	b)	NapA	and	c)	NarG.		
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2.2.2	The	role	of	recF	and	recB	in	quinolone-mediated	death	
	 RecB	 and	 recF	 proteins	 are	 involved	 in	 repairing	 DSBs	 and	 SSBs	 breaks	respectively.	 As	 such,	 mutants	 of	 these	 enzymes	 are	 indicative	 of	 the	 deleterious	DSBs	 and	 SSBs	 present.	 It	 has	 been	 shown	 that	 removing	 recB	 sensitizes	 cells	 to	bactericidal	antibiotics,	 indicating	 that	DSBs	are	present	 in	antibiotic	 treated	cells,	and	 require	 repair	 (Foti,	 et	 al.,	 2012).	 Surprisingly,	 however,	 we	 found	 that	 recF	sensitizes	cells	to	DNA	damage	under	beta-lactam	and	quinolone	stress	(Figure	2.5).	Removing	recF	greatly	reduces	antibiotic	susceptibility.	We	hypothesize	that	recF	is	futilely	repairing	SSBs,	possibly	at	replication	forks,	leading	to	genotoxic	damage.																																											
	
	
	
	
	
	
	
	
	
	
Figure	2.5:	The	role	of	recB	and	recF	in	nalidixic	acid	treated	cells.	We	treated	cells	with	nalidixic	 acid	 (100	ug/mL)	over	 time.	Removing	 recB	 sensitizes	 cells	 to	
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antibiotics	 (red).	 However,	 removing	 recF	 helps	 cells	 survive	 when	 treated	 with	nalidixic	acid	(blue).		
	
2.2.3	The	role	of	xthA	and	nfo	in	quinolone-mediated	death		 Next	we	explored	the	role	of	xthA	and	nfo	in	quinolone-mediated	death.	XthA	is	an	exonuclease,	specifically	a	5’	apurinic/apyrimidinic	(AP)	endonuclease,	which	performs	 the	 nicking	 action	 after	 glycosylase-mediated	 base	 removal.	 Nfo,	 also	called	 endonuclease	 IV,	 is	 the	 second	 5’	 AP	 endonuclease	 present	 in	 E.	 coli.	 In	 a	mutant	 of	 xtha/nfo	 we	 found	 that	 nalidixic	 acid	 activity	 was	 highly	 sensitized	(Figure	 2.6).	 Thus,	 xtha	 and	 nfo	 action	 is	 required	 to	 repair	 lethal	 damage	 by	quinolones.		Interestingly,	the	xtha/nfo	mutant	behaves	similarly	to	recB,	in	that	the	sensitization	is	instant	with	no	initial	lag	phase.	This	indicates	that	the	damage	that	xtha/nfo	 is	 required	 to	 repair	appears	 right	after	 treatment	or	becomes	genotoxic	after	treatment.	One	explanation	for	the	sensitivity	of	this	mutant	is	that	without	it,	base-excision	repair	results	in	abasic	sites,	which	are	toxic	to	the	cell	(Lovett	2011).	Another	hypothesis	is	that	the	increased	basal	level	of	recombination	in	this	mutant	(data	not	shown)	becomes	toxic	in	the	presence	of	nalidixic	acid.	
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Figure	2.6:	Role	of	xtha/nfo	in	nalidixic	acid	treated	cells.	We	treated	cells	with	nalidixic	 acid	 (100	 ug/mL)	 over	 time.	 Removing	 xtha/nfo	 sensitizes	 cells	 to	antibiotics	(green)	with	no	initial	lag	phase.		
2.2.4	Characterization	of	number	and	progression	of	DSBs		 DSBs	 can	 cause	 cell	 death	 and	 are	 implicated	 as	 the	 primary	 cause	 of	quinolone-mediated	death;	however,	no	one	has	ever	studied	how	many	DSBs	are	needed	 to	 kill	 a	 cell	 and	 how	 the	 number	 of	 breaks	 progresses	 over	 time.	 Susan	Rosenberg’s	 group	 engineered	 a	 protein	 to	 visualize	 double-stranded	 breaks	 in	DNA,	 called	 GamGFP,	 which	 can	 enable	 this	 type	 of	 study.	 Gam	 is	 found	 in	 the	bacteriophage	 Mu	 and	 binds	 to	 double-stranded	 ends.	 Shee	 et	 al.	 created	 a	 Tet-
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inducible	GamGFP	construct,	which	localizes	GFP	to	DSBs	(Shee,	Cox	et	al.	2013).		 Belenky	 et	 al.	 did	 the	 first	 study	 imaging	 DSB	 foci	 under	 antibiotic	 stress	using	 the	 GamGFP	 construct	 (Belenky,	 Ye	 et	 al.	 2015).	 We	 found	 that	 antibiotic	stress	results	in	DSBs	in	all	bactericidal	antibiotic	conditions.	These	DSBs	are	visible	as	clear	foci	using	the	GamGFP	construct	(Figure	2.7).		
	
Figure	2.7:	GamGFP	foci	are	visible	in	cells	treated	with	antibiotics	(Belenky,	
Ye	 et	 al.	 2015).	 Cells	 were	 treated	 for	 2	 hours	 with	 10mM	 H2O2,	 2.5	 ug/mL	
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ampicillin,	 10	 ug/mL	 kanamycin,	 or	 125	 ng/mL	 norfloxacin.	 a)	 Selected	 images	show	GamGFP	 foci	under	varying	 treatments.	b)	The	percent	of	 cells	with	 foci	are	shown.	Cells	treated	with	H2O2	and	antibiotics	have	significantly	more	%	cells	with	foci	than	un-treated	cells.				 One	 method	 in	 which	 DNA	 repair	 leads	 to	 sensitivity	 by	 antibiotics	 is	 by	promoting	 the	 creation	of	DSBs.	To	 see	 if	 the	phenotypes	we	 found	 for	killing	are	related	 to	 DSBs,	 we	 used	microscopy	 to	 perform	 single-cell	 imaging	 of	 breaks	 in	cells	treated	with	antibiotics	over	time.		
																			 	
Figure	2.8:	DSB	over	 time	 in	nalidixic	 acid	 treated	 cells.	DSB	per	cell	(n>100)	were	 counted	 after	 15-minute	 to	 90-minute	 treatments	 with	 nalidixic	 acid	(100μg/mL)	and	fluorescent	microscopy	imaging.	The	mean	#	foci	is	plotted	against	treatment	time.	
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	 We	first	 looked	at	wildtype	cells	 treated	with	100μg/mL	nalidixic	acid	over	time	to	see	the	progression	of	DSBs	after	treatment	(Figure	2.8).	We	found	that	the	mean	number	of	 foci	 increases	primarily	within	 the	 first	 30	minutes	of	 treatment	and	 levels	off	after	60	minutes	at	approximately	8	DSBs.	This	corresponds	well	 to	the	rapid	increase	in	death	seen	in	the	first	hour	of	treatment.	The	fact	that	there	are	a	mean	of	2	double-stranded	breaks	by	15	minutes	agrees	with	the	rapid	death	seen	in	 recB	mutant	 that	 requires	 just	 a	 single	 break	 to	 die;	 however,	 this	 number	 of	breaks	does	not	lead	to	death	when	recB	is	present	as	seen	by	the	initial	stasis	in	the	wildtype	(Figure	2.5).			 We	then	plotted	histograms	of	 the	percent	of	cells	 in	bins	of	 the	number	of	foci.	 The	 histograms	 follow	 a	 Gaussian	 distribution	 with	 the	 spread	 of	 cells	increasing	over	 time.	By	1	hour,	 there	are	cells	with	over	20	DSBs,	 indicating	 that	cells	can	manage	a	large	number	of	DSBs	without	dying.	The	number	of	breaks	we	see	is	within	the	order	of	magnitude	of	breaks	seen	using	in	situ	DNA	fragmentation	(Tamayo,	Santiso	et	al.	2009).		
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Figure	2.9:	Histogram	of	DSBs	per	cell	over	time	after	nalidixic	acid	treatment.	Histograms	 of	%cells	 in	 bins	 of	 #	 of	 foci	 for	 wildtype	 cells	 (n>100)	 treated	 with	100μg/mL	of	nalidixic	acid	for	a)	15	minutes,	b)	30	minutes,	c)	60	minutes	and	d)	90	minutes.			 We	next	assessed	the	number	of	DSBs	in	the	mutY/mutM,	recF	and	xthA/nfo	mutants	(Figure	2.10).	The	mean	of	breaks	is	consistent	between	mutY/mutM,	recF	and	wildtype	 at	 15	minutes,	while	 xthA/nfo	 has	 a	 higher	mean	 of	 breaks.	 After	 1	hour	of	 treatment,	 the	number	of	breaks	 in	mutY/mutM	and	recF	 is	slightly	 lower	than	wildtype,	and	xtha/nfo	is	significantly	lower.		
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Figure	2.10:	Mean	DSBs	for	mutY/mutM,	xthA/nfo	and	recF.	DSB	per	cell	(n>60)	were	 counted	 after	 15-minute	 and	 60-minute	 treatments	 with	 nalidixic	 acid	(100μg/mL)	 and	 fluorescent	 microscopy	 imaging	 in	 wildtype,	 mutY/mutM,	xthA/nfo	and	recF	mutants.	The	mean	#	foci	is	plotted	against	treatment	condition.				 When	assessing	the	distribution	of	breaks	(Figure	2.11),	one	can	see	that	the	recF	profile	is	shifted	to	the	left	compared	to	wildtype	indicating	that	cells	without	recF	have	 fewer	DSBs.	This	 further	 indicates	 that	recF	action	results	 in	DSBs	after	quinolone	treatment.	It	is	hypothesized	that	the	recF	mutant	is	toxic	when	it	forms	a	complex	with	recA	at	single-stranded	gaps	(Theodore,	Lewis	et	al.	2013).	The	DSB	data	 implies	 that	 recF-mediated	DSB	production	 is	also	a	potential	mechanism	 for	recF	toxicity.	
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	 MutY/mutM	has	a	DSB	profile	shifted	to	the	left,	indicating	that	overall,	cells	have	 fewer	 DSBs.	 This	 is	 consistent	 with	 data	 from	 Foti	 et	 al.,	 in	 which	 they	hypothesize	that	mutY	and	mutM	glycosylase	activity	leads	to	DSB	formation.			 Interestingly,	 the	profile	of	xthA/nfo	 is	bimodal,	where	the	majority	of	cells	have	no	breaks,	while	 some	have	 close	 to	40.	The	 fact	 that	 so	many	 cells	have	no	breaks	is	surprising	considering	the	increased	sensitivity	of	this	mutant	to	nalidixic	acid.	 One	 hypothesis	 to	 explain	 this	 is	 that	 the	 majority	 of	 cells	 with	 breaks	 are	dying	 rapidly	 and	 are	 not	 imaged;	 thus	 instead	 of	 seeing	 the	 complete	 picture	 of	DSBs,	we	are	only	seeing	the	cells	which	are	able	 to	survive.	This	 is	unlikely	since	cells	with	even	40	breaks	are	surviving.	Another	hypothesis	is	that	xthA	and	nfo	are	required	to	produce	the	majority	of	breaks	that	we	see	in	the	wildtype;	it	is	possible	that	 their	 exonuclease	 activity	 results	 in	 DSBs	 through	 closely	 spaced	 nicks.	 This	again	 is	 surprising	 considering	 the	 high	 sensitivity	 of	 xthA/nfo—could	 it	 be	 that	DSBs	are	not	 required	 for	death	by	quinolones?	Further	analysis	of	 this	mutant	 is	required	to	understand	the	surprising	phenotype.	
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Figure	2.11:	DNA	repair	mutants	change	the	distribution	of	GamGFP	foci.	Cells	(n>50)	 were	 treated	 for	 15	 minutes	 and	 1	 hour	 with	 nalidixic	 acid	 (100ug/mL).	GamGFP	 foci	 per	 cell	 were	 counted	 and	 the	 histogram	 was	 fit	 to	 a	 gaussian	distribution.	 a)	 The	 distribution	 of	 recF	 mutant	 (purple)	 is	 shifted	 to	 the	 left	compared	 to	 wildtype	 (blue).	 b)	 The	 distribution	 of	 mutY/mutM	 (red)	 mutant	 is	shifted	to	the	left	and	more	widely	distributed	compared	to	wildtype	(blue).	c)	The	
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distribution	of	xthA/nfo	mutant	(green)	has	a	bimodal	distribution	of	cells	with	very	few	breaks	or	cells	with	a	high	number	of	breaks	compared	to	wildtype	(blue).		
2.2.5	DNA	damage	in	other	antibiotics		 There	is	some	evidence	that	DNA	damage	contributes	to	death	by	antibiotics	that	do	not	target	the	DNA:	aminoglycosides,	which	target	protein	translation,	and	beta-lactams,	which	target	the	cell	wall	(Foti,	Devadoss	et	al.	2012,	Belenky,	Ye	et	al.	2015).	We	explored	whether	the	phenotypes	for	DNA	damage	mutants	that	we	saw	with	 nalidixic	 acid	 would	 be	 present	 for	 gentamicin,	 an	 aminoglycoside,	 and	ampicillin,	a	beta-lactam	(Figure	2.12).				 We	 treated	 DNA	 damage	 mutants	 with	 5	 μg/mL	 ampicillin	 and	 4	 μg/mL	gentamicin	and	plotted	CFU/mL	over	time.	We	found	that	DNA	damage	mutants	do	have	 phenotypes	 to	 ampicillin	 and	 gentamicin,	 supporting	 the	 idea	 that	 these	enzymes	 act	 on	 downstream	 pathways	 not	 directly	 related	 to	 drug-target	interactions.			 Because	 of	 the	 literature	 showing	 ROS	 as	 a	 common	 mechanism	 for	antimicrobial	 sensitivity,	 we	 first	 studied	 mutants	 related	 to	 oxidative	 damage:	mutY/mutM,	 nei/nth	 and	 mutY/mutM/nei/nth.	 We	 found	 that,	 just	 as	 with	quinolones,	 these	mutants	 are	 less	 sensitive	 to	 ampicillin	 and	 gentamicin	 (Figure	2.11	 a,	 b).	 The	 quadruple	mutant	 performs	 5-fold	 better	 than	 the	wildtype	when	treated	 with	 ampicillin,	 and	 100-fold	 better	 than	 wildtype	 when	 treated	 with	gentamicin.			
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Figure	2.12:	DNA	damage	mechanism	 for	 beta-lactams	 and	 aminoglycosides.	Kill	curves	for	various	DNA	damage	mutants	are	shown.	Mutants	were	treated	with	
		
31	
5	 μg/mL	 ampicillin	 (a,	 c,	 e)	 and	 4	 μg/mL	 gentamicin	 (b,	 d,	 f)	 over	 time.	 a,	 b)	mutY/mutM	 and	 nei/nth	 protect	 slightly	 in	 both	 drug	 treatments,	 while	mutY/mutM/nei/nth	protects	about	5-fold	 in	ampicillin	 treated	cells	and	100-fold	in	gentamicin	 treated	cells.	 c,	d)	 recB	 is	more	sensitive	 in	both	conditions,	 though	with	 an	 initial	 lag	 phase;	 recF	 is	 less	 sensitive	when	 treated	with	 ampicillin,	 and	more	sensitive	when	treated	with	aminoglycoside.	e,	f)	nfi	is	more	sensitive	in	both	treatments,	while	xthA/nfo	is	similar	to	wildtype.			 	Since	we	see	such	strong	phenotypes	for	these	mutants	with	ampicillin	and	gentamicin,	 it	 indicates	 that	 these	 glycosylases	 work	 downstream	 of	 DNA	 gyrase	inhibition.	 It	 is	 possible	 that	 the	 ROS	 that	 is	 produced	 after	 treatment	with	 these	drugs	leads	to	oxidative	DNA	lesions.			 We	next	tested	recF	and	recB	mutants	to	see	the	effect	of	single	and	double-stranded	breaks	on	sensitivity	by	ampicillin	and	gentamicin	(Figure	2.12	c,d).	Like	in	quinolones,	we	found	that	recB	is	more	sensitive	to	both	drugs.	However,	unlike	in	quinolones,	 this	 sensitivity	 has	 a	 lag	 phase,	 indicating	 that	 breaks	 do	 not	 appear	right	after	treatment,	and	are	likely	due	to	downstream	mechanisms.	RecF	is	slightly	less	sensitive	than	wildtype	after	ampicillin	treatment,	while	it	is	more	sensitive	to	gentamicin.	 Thus,	 after	 gentamicin	 treatment	 recF	 is	 needed	 to	 correct	 problems,	while	after	ampicillin	treatment	it	is	toxic	to	the	cells.			 Finally,	 we	 tested	 xtha/nfo	 and	 nfi.	 Nfi	 is	 more	 sensitive	 in	 all	 conditions,	indicating	that	 its	action	is	downstream	of	drug-target	 interactions.	 It	 is	 important	
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to	note	 that	 the	nfi	mutant	 is	more	 sensitive	 to	 all	 drugs	making	 it	 an	 interesting	target	to	understand	in	more	detail.	XthA/nfo	is	like	the	wildtype	in	both	conditions	indicating	that	its	action	is	only	relevant	in	quinolone	treated	cells.	This	fits	with	the	phenotype	seen	in	quinolone	treated	cells	where	the	mutant	sensitivity	occurs	right	after	treatment	with	no	lag	phase.		
2.2.6	DNA	damage	in	dam-mediated	death	by	ampicillin		 We	showed	another	example	of	DNA	damage-induced	death	by	ampicillin	in	Cohen	et	al.	 (Cohen,	Ross	et	al.	2016).	We	showed	that	deoxyadenosine	methylase	(dam)	mutants	 are	 sensitized	 to	 low	 concentrations	 of	 ampicillin	 and	 quinolones.	Using	 SMRT	 technology,	 we	 found	 no	 difference	 between	 the	 methylation	 of	ampicillin-treated	 and	 un-treated	 cells.	 Thus,	 we	 reasoned	 that	 dam	 provides	structural	 support	 to	 the	 DNA	 rather	 than	 regulatory	 support.	 Using	 a	 genetic	approach,	 it	was	 established	 that	 the	dam	methylome	 is	 required	 to	prevent	 cells	from	 accumulating	 DNA	 damage.	 It	 was	 found	 that	 removing	 mismatch	 repair	enzymes	mutH	and	dinB	 from	dam	mutant	results	 in	DNA	damage	reduced	to	WT	levels,	 indicating	 that	mutH	 and	 dinB	 contribute	 to	 DNA	 damage	 in	 dam	mutants	under	antibiotic	stress	(Figure	2.13)	(Cohen,	Ross	et	al.	2016).	
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Figure	2.13:	DNA	damage	contributes	to	dam-mediated	death	(Cohen,	Ross	et	
al.	 2016).	 Log-phase	E.	 coli	 grown	 in	 LB	 alone	or	with	hydrogen	peroxide	 (H2O2;	100	 mM)	 or	 ampicillin	 (2.5	 µg/ml)	 for	 1	 hour	 was	 assayed	 for	 DNA	 breaks	 by	TUNEL	 analysis.	 Data	 are	 shown	 as	 the	 mean	 percent	 of	 cells	 positive	 for	 DNA	damage	±	s.e.m.	of	n	=	3	independent	experiments.	Statistical	comparisons	between	each	 mutant	 strain	 and	 wild-type	 bacteria	 were	 not	 significant	 unless	 otherwise	indicated:	****P	<	0.0001.	
	
2.3	CONCLUSION	
	 In	 this	 chapter	 I	 have	 presented	 data	 linking	 DNA	 damage	 to	 antibiotic-induced	death.	I	first	showed	that	oxidized	bases	are	related	to	death	by	antibiotics.	A	 common	oxidized	 lesion,	 8-oxo-guanine,	 has	been	 implicated	 in	 antibiotic	death	(Foti,	 Devadoss	 et	 al.	 2012).	 We	 expanded	 this	 to	 include	 bulky	 lesions	 such	 as	pyrimidine	dimers	recognized	by	glycosylases	nei	and	nth.	We	further	found	that	nfi	and	 xthA/nfo	 are	 important	 repair	 enzymes,	which	 help	 cells	 overcome	 death	 by	quinolones.	 Finally,	 we	 found	 that	 recF	 is	 less	 sensitive	 to	 quinolone	 action,	indicating	that	the	repair	of	SSBs	by	recF	is	toxic	to	the	cells.			
		
34	
	 DSBs	 have	 been	 implicated	 in	 quinolone-mediated	 death,	 but	 number	 of	breaks	 and	 mechanism	 of	 break	 formation	 is	 not	 well	 understood.	 Using	 the	GamGFP	construct	engineered	in	Susan	Rosenberg’s	 lab	(Shee,	Cox	et	al.	2013)	we	found	 that	 quinolones	 induce	 DSBs	 after	 treatment,	 hitting	 a	 maximum	 mean	 of	approximately	 8	 DSBs.	 Mutants	 in	 DNA	 repair,	 such	 as	 mutY/mutM,	 recF	 and	xthA/nfo	have	a	reduced	number	of	DSBs	compared	to	the	wildtype.			 Finally,	we	 showed	 that	DNA	 repair	 is	 a	 factor	not	 just	 in	quinolone	death,	but	 in	 ampicillin	 and	 gentamicin	 death	 as	 well.	 Thus,	 DNA	 damage	 repair	 is	 an	important	downstream	consequence	of	antibiotic	treatment.		
2.4	METHODS	
2.4.1	Strain	and	mutant	construction	
	 For	 all	 sensitivity	 studies	 we	 used	 Escherichia	 coli	 K-12	 MgC1	 (Gutierrez,	Laureti	 et	 al.	 2013)	 and	 for	 GamGFP	 studies	 we	 used	 strain	 SMR14015	 kindly	provided	 by	 Shee	 et	 al.	 (Shee,	 Cox	 et	 al.	 2013).	 All	 mutants	 were	 built	 using	 P1	transduction	from	the	Keio	collection.	Knockout	strains	were	checked	for	accuracy	by	PCR	amplification	and	gel	electrophoresis.		
2.4.2	Sensitivity	Assay		 Overnight	cultures	of	strains	were	diluted	1/10,000	in	LB	(Difco)	and	grown	in	37	°C	until	they	reached	an	OD	between	0.1	and	0.2.	Cells	were	then	treated	with	
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antibiotic	for	varying	lengths	of	time.	Cells	were	serially	diluted	in	PBS	on	a	96-well	plate	and	plated	on	LB	agar	 (Difco)	plates.	The	plates	were	 incubated	at	37°C	and	colonies	were	counted,	reported	as	colony-forming	units	per	mL	(CFU/mL).			
2.4.3	GamGFP	Assay		 Overnight	 cells	 were	 diluted	 1/10000	 in	 LB.	 	 Thirty	 minutes	 before	 cells	reached	 an	 OD600	 between	 0.1	 and	 0.2,	 ATC	 (2	 μg/mL)	 was	 added	 to	 induce	gamGFP	expression.	After	thirty	minutes,	cells	were	spun	down	5	minutes	at	3000	rpm	and	re-suspended	in	fresh	LB	and	100μg/mL	nalidixic	acid	for	varying	amounts	of	 time.	 At	 each	 time	 point,	 cells	 were	 moved	 to	 ice.	 Before	 imaging,	 cells	 were	incubated	with	1mM	DAPI	for	5	minutes.	Then,	cells	were	spread	on	a	pre-made	1%	agarose	pad	on	a	glass	slide.	Cells	were	imaged	using	auto-exposure	with	a	Nikon	TI-E	 microscope.	 Images	 were	 analyzed	 using	 ImageJ.	 For	 Figure	 2.7,	 the	 GamGFP	protocol	is	described	in	Belenky	et	al.	(Belenky,	Ye	et	al.	2015).		
2.4.4	Tunel	Assay		 The	Tunel	assay	is	described	in	detail	in	Cohen	et	al.	(Cohen,	Ross	et	al.	2016)	Briefly,	 log-phase	 cultures	 were	 transferred	 to	 a	 96-well	 plate	 and	 treated	 with	ampicillin	(2.5	µg/ml)	or	hydrogen	peroxide	(100	mM)	37	°C	and	900	r.p.m.	Bacteria	were	pelleted	by	 centrifugation	at	3,000g	 for	5	min	and	 resuspended	 in	200	µl	of	cold	4%	paraformaldehyde	in	PBS	and	incubated	at	room	temperature	for	30	min	to	
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allow	 fixation.	Bacteria	were	 centrifuged	 again	 and	 resuspended	 in	200	µl	 of	 cold	permeabilization	buffer	(0.1%	Triton	X-100	in	0.1%	sodium	citrate).	After	2	min	at	room	temperature,	bacteria	were	centrifuged	and	washed	in	PBS.	After	pelleting	the	cells	 and	 discarding	 the	 supernatant,	 cells	 were	 resuspended	 in	 50	 µl	 of	 TUNEL	labeling	 mix	 (dUTP-FITC	 and	 TdT	 enzyme)	 or	 50	 µl	 of	 TUNEL	 labeling	 reagent	(dUTP-FITC)	according	to	the	manufacturer’s	instructions	(Roche,	In	Situ	Cell	Death	Detection	Kit,	Fluorescein).	Bacteria	were	stained	for	1	h	at	37	°C.	Cells	were	then	washed	 twice	 with	 PBS,	 resuspended	 in	 1	 µg/ml	 propidium	 iodide	 in	 PBS	 and	analyzed	 by	 flow	 cytometry	 (BD	 LSR	 Fortessa).	 Propidium	 iodide–negative	 cells,	which	 lack	 genomic	 material,	 were	 excluded	 from	 the	 analysis.	 Gating	 was	determined	using	 single-color	and	unstained	controls	 as	 references.	For	 statistical	analysis,	 background	 staining	with	 labeling	 reagent	 only	was	 subtracted	 for	 each	sample	 to	 account	 for	 treatment-dependent	 shifts	 in	 autofluorescence	 or	 stain	retention.		
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CHAPTER	THREE:	MUTAGENESIS		
3.1	INTRODUCTION	
	 Antibiotic	resistance	is	a	rising	problem,	which	requires	assessment.	The	first	multi-drug	 resistant	 strain	 of	 bacteria	 appeared	 as	 early	 as	 1955,	 and	 such	resistance	 has	 only	 been	 growing	 over	 the	 last	 few	 decades	 (Davies	 1995).	 One	approach	to	understanding	resistance	is	by	studying	mutagenesis	during	antibiotic	treatment.	
	 The	 neo-Darwin	 view	 of	 mutagenesis	 is	 that	 it	 is	 constant	 and	 gradual.	However,	more	 recently	 it	 is	 becoming	 accepted	 that	mutagenesis	 can	 occur	 as	 a	response	to	stress;	this	type	of	mutagenesis	has	been	termed	adaptive	mutagenesis	or	 stress-induced	 mutagenesis.	 Stress-induced	 mutagenesis	 has	 been	 studied	extensively	at	 sub-inhibitory	 concentrations	of	 antibiotics.	 	Cells	 induce	 responses	such	as	the	SOS	response	and	RpoS	regulon	to	protect	them	from	antibiotic	action	(Baharoglu	and	Mazel	2011,	Thi,	Lopez	et	al.	2011,	Gutierrez,	Laureti	et	al.	2013).		The	SOS	response	is	turned	on	in	response	to	unprotected	single	strands	of	DNA;	the	inactivation	of	LexA	during	the	SOS	response	results	in	the	expression	of	400	genes,	some	error-prone,	related	to	DNA	repair	(Friedberg,	Walker	et	al.	1995,	Courcelle,	Khodursky	 et	 al.	 2001).	 Quinolones,	 which	 target	 DNA	 replication,	 unsurprisingly	create	problems	in	the	DNA	and	result	in	activation	of	the	SOS	response.	However,	other	 antibiotics	 such	 as	beta-lactams	also	 initiate	 the	 SOS	 response,	mediated	by	the	 two-component	 system	 DpiAB	 (Miller,	 Thomsen	 et	 al.	 2004).	 Gutierrez	 et	 al.	
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implicated	the	RpoS	sigma	factor	in	leading	to	increased	mutagenesis	when	treated	with	beta-lactam	antibiotics	(Gutierrez,	Laureti	et	al.	2013).	The	RpoS	sigma	factor	is	 upregulated	 in	 a	 wide	 array	 of	 stressful	 conditions,	 including	 heat	 shock,	starvation,	acidic	pH	and	osmotic	shock	(Battesti,	Majdalani	et	al.	2011).			 Kohanski	 et	 al.	 extended	 the	mechanism	 for	 stress-induced	mutagenesis	 to	low	 concentrations	 of	 antibiotics	 to	 include	 the	 production	 of	 ROS	 (Kohanski,	DePristo	et	al.	2010).	They	found	that	the	increases	in	mutation	rate	after	treatment	with	sub-lethal	doses	of	norfloxacin,	ampicillin	and	kanamycin	was	diminished	with	the	 addition	 of	 100mM	 thiourea,	 a	 ROS	 scavenger.	 They	 hypothesized	 that	 ROS	increased	mutagenesis	through	a	pathway	in	which	it	damaged	the	DNA.		 To	 our	 knowledge,	 mutagenesis	 at	 high	 doses	 of	 antibiotics	 has	 not	 been	studied.	Understanding	how	different	doses	of	antibiotics	affect	 the	mutation	rate,	and	 elucidating	 a	 mechanism	 for	 this	 increase,	 could	 lead	 to	 new	 targets	 for	eliminating	resistance.			
3.2	RESULTS	
3.2.1	Stress-Induced	Mutagenesis	by	Quinolones		 Antibiotic	sensitivity	can	be	modulated,	through	mutations	in	genes	affecting	antibiotic	 efficacy.	 The	mutation	 rate	 of	 cells	 is	 therefore	 a	 good	 indication	 of	 the	genetic	instability	that	can	lead	to	de	novo	and	adaptive	resistance.	Using	quinolones	as	 a	 drug	 model,	 we	 aimed	 to	 characterize	 how	 antibiotics	 impairing	 genomic	stability	can	modulate	mutation	rate.	
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	 For	 these	 studies	 we	 used	 an	 engineered	 Escherichia	 coli	 strain	 with	 a	constitutively-on	λcI	(Ind-)	cassette	that	represses	a	λpR	promoter	linked	to	a	tetA	resistance	 gene	 (Bjedov,	 Dasgupta	 et	 al.	 2007).	 Using	 this	 strain,	we	 performed	 a	forward	mutagenesis	 assay	 that	 allows	 us	 to	 score	 any	 loss	 of	 function	mutation	within	the	1022	bp	of	the	CI	gene.	We	treated	cells	with	a	pulse	of	nalidixic	acid	for	90	minutes	followed	by	an	overnight	recovery	period	and	determined	the	frequency	of	 tetracycline	 resistant	 mutants	 compared	 to	 untreated	 cells.	We	 found	 that	 the	fold-change	in	mutation	frequency	over	concentration	is	a	bimodal	curve,	and	that	the	 two	 peaks	 of	 this	 curve	 correspond	 to	 the	 two	 modes	 of	 killing	 seen	 in	quinolones	(Crumplin	and	Smith	1975)	(Figure	3.1a).	Interestingly,	there	is	a	small	range	 of	 concentrations,	 between	 90	 and	 150	 μg/mL,	 which	 correspond	 to	maximum	 killing	 and	minimum	mutation	 frequency.	 The	 fact	 that	 there	 is	 such	 a	narrow	optimal	range	in	which	antibiotic	treatment	is	effective	motivates	the	study	of	how	quinolones	affect	cell	physiology	and	DNA	instability	at	sub-optimal	doses.		
	
Figure	3.1:	Characterization	of	stress-induced	mutagenesis	by	nalidixic	acid.	a)	Fold	 change	 in	 TetR	mutation	 frequency	 after	 90-minute	 treatment	with	 nalidixic	
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acid	and	regrowth	under	no	antibiotic	 selection	at	a	 range	of	 concentrations.	Fold	change	 in	TetR	mutation	 frequency	 compared	 to	untreated	 cells	 is	plotted	 in	blue.	The	 killing	 profile,	 %CFU/mL,	 is	 plotted	 in	 black.	 b)	 Cells	 were	 also	 selected	 on	200μg/mL	 rifampicin	 after	 90-minute	 treatment	with	 nalidixic	 acid	 and	 regrowth	under	no	antibiotic	selection.	 	The	fold	change	of	RifR	mutation	frequency	compare	to	untreated	cells	is	plotted	in	red.			 Bacterial	 cells	 become	 resistant	 to	 rifampicin	 through	 single	 nucleotide	substitutions	(Petrenik,	Mindlin	et	al.	1984).	To	assess	if	the	peaks	in	the	mutation	frequency	 curve	 are	 caused	by	 single	nucleotide	 substitutions	or	other	mutations,	we	treated	cells	for	90	minutes	with	nalidixic	acid,	regrew	over	night	in	fresh	media	and	 plated	 on	 200ug/mL	 rifampicin	 plates	 (Figure	 3.1b).	We	 found	 that	RifR	 cells	still	peaked	at	around	50μg/mL	nalidixic	acid.	However,	there	was	no	second	peak	in	the	rifampicin	resistant	cells,	thus	indicating	that	the	second	peak	of	tetracycline	resistant	cells	was	enriched	in	mutations	other	than	single	nucleotide	substitutions.		We	focused	our	initial	characterization	efforts	on	the	first	peak,	at	50	μg/mL	of	 nalidixic	 acid.	 A	 plot	 of	 the	 histogram	 of	 mutation	 frequencies	 from	 over	 75	samples	 shows	 that	 the	mutation	 frequencies	 before	 and	 after	 treatment	 follow	 a	Gaussian	distribution	with	medians	of	5	x	10-6	TetR/(total	cells)	for	untreated	cells	and	6	x	10-7	TetR/(total	cells)	for	treated	cells	(Figure	3.2a).	The	entire	population	of	cells	homogenously	increases	with	treatment.	We	then	sequenced	the	CI	construct	of	these	cells	and	analyzed	the	mutation	
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profile	before	and	after	treatment	(Figure	3.2b).		The	frequency	of	all	mutations	was	increased	after	treatment	with	nalidixic	acid.	SNPs	and	deletions	were	increased	the	most,	 implying	 that	mutations	are	 likely	 to	occur	during	replication.	G/C	deletions	were	 the	 most	 abundant,	 with	 a	 100-fold	 increase	 after	 treatment.	 The	 other	mutations	 had	 a	 fold-change	 increase	 of	 17	 or	 less	 (Figure	 3.2c).	We	 hypothesize	that	 the	 G/C	 deletions	 are	 a	 result	 of	 DNA	 damage	 repair	 through	 translesion	polymerases.	
	
Figure	3.2:	Characterization	of	the	mutation	profile	at	50	μg/mL	nalidixic	acid.	a)	A	histogram	of	mutation	frequencies	of	TetR	cells	for	un-treated	(black)	and	cells	treated	with	90	minutes	of	50	ug/mL	nalidixic	acid	(red).	b)	Mutation	 frequencies	for	individual	mutations	for	un-treated	(black)	and	cells	treated	with	90	minutes	of	
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50	ug/mL	nalidixic	acid	(red).	c)	Fold	change	in	mutation	frequency	over	un-treated	for	each	mutation.		
3.2.2	The	role	of	translesion	polymerases	on	quinolone-induced	mutagenesis	To	confirm	that	G/C	deletions	were	due	to	translesion	polymerase	action,	we	made	a	mutant	of	the	three	translesion	polymerases	in	E.	coli—Pol	II	(polB),	Pol	IV	(dinB),	 and	 PolV	 (umuDC).	 I	will	 refer	 to	 this	 knockout	 as	 Pol3X.	 Using	 the	 same	protocol	as	for	wildtype	cells,	we	assessed	the	cI-mutation	profile	at	a	concentration	of	50	μg/mL	nalidixic	acid	(Figure	3.3).	We	found	that	the	Pol3X	mutant	had	a	7.3	fold	increase	in	mutation	frequency,	compared	to	wildtype	cells,	which	had	an	11.6	fold	 increase	(Figure	3.3a).	 	As	expected,	Pol3X	cells	had	a	 fold-change	 increase	 in	G/C	deletions	of	20.3,	about	5	 fold	 less	 than	 the	 increase	 in	wildtype	cells	 (Figure	3.3b).	This	indicates	that	Pol3X	action	is	required	for	the	formation	of	a	majority	of	G/C	 deletions.	 There	 is	 an	 increase	 in	 indels	 (insertions	 and	 deletions),	 though	because	 of	 the	 small	 number	 of	 indels,	 this	 increase	 could	 be	 by	 chance.	 There	 is	also	a	decrease	in	transversion	and	transition	mutants	in	the	Pol3X	mutant,	which	is	expected	given	the	replication-error	prone	behavior	of	translesion	polymerases.	
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Figure	 3.3:	 The	 effect	 of	 translesion	 polymerases	 on	mutation	 frequency.	 a)	The	 fold	 change	 in	 mutation	 frequency	 for	 wildtype	 cells	 and	 polII/polIV/polV	mutant	 (referred	 to	 as	 Pol3X).	 b)	 The	 fold	 change	 in	 the	 mutation	 frequency	 for	specific	mutations	for	wildtype	(blue)	and	Pol3X	(gray).			
3.2.3	The	role	of	DNA	repair	mutants	on	mutation	frequency	We	 next	 explored	 where	 the	 original	 damage,	 which	 the	 translesion	polymerases	are	converting	to	C/G	deletions,	is	coming	from.	We	hypothesized	that	we	 could	modulate	 the	mutation	 frequency	 by	 knocking	 out	DNA	 repair	 enzymes	related	to	base	excision	repair,	specifically	DNA	glycosylases	and	exonucleases.	We	knocked	 out	 genes	 involved	 in	 the	 repair	 of	 oxidative	 lesions,	 the	 glycosylases	—	
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mutY,	 mutM,	 nei	 and	 nth	—	 and	 exonucleases	—	 xthA	 and	 nfo.	We	 sampled	 the	mutation	frequency	of	20	or	more	samples	treated	with	50	μg/mL	of	nalidixic	acid,	and	 found	 that	 the	 median	 mutation	 frequency	 decreases	 in	 all	 mutants	 (Figure	3.4a).	
	
Figure	3.4:	DNA	repair	enzymes’	role	in	mutagenesis.	a)	The	median	fold	change	in	mutation	 frequency	 for	mutants	 in	 DNA	 repair	 enzymes	 (nn	 =	ΔneiΔnth,	 ym	 =	
ΔmutyΔmutm,	ym/nn	=	ΔmutyΔmutmΔneiΔnth,	xn	=	ΔxthaΔnfo).	b)	A	comparison	of	fold	 change	 in	 mutation	 frequency	 for	 wildtype	 (blue)	 and	 xn	 (red)	 at	concentrations	of	nalidixic	acid	ranging	from	2	to	100	μg/mL.		The	mutants	nei/nth,	muty/mutm	and	the	combination	are	less	sensitive	to	antibiotic	 killing	 than	 the	 wildtype	 strain;	 thus,	 we	 were	 not	 concerned	 that	 the	concentration	we	used	would	be	too	high	to	see	mutagenesis.	Because	xthA/nfo	 is	significantly	 more	 sensitive	 to	 quinolone	 treatment,	 we	 hypothesized	 that	 the	
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decrease	 in	 mutation	 frequency	 for	 xthA/nfo	 could	 be	 due	 to	 the	 concentration	being	 too	 high.	 To	 control	 for	 this,	 we	 assessed	 the	 fold	 change	 of	 mutation	frequency	for	xthA/nfo	and	wildtype	at	low	concentrations	of	nalidixic	acid,	where	xthA/nfo	 is	 not	 killed	 significantly.	 We	 found	 that	 the	 fold	 increase	 in	 mutation	frequency	is	approximately	1	at	lower	concentrations	(Figure	3.4b),	thus	confirming	our	findings	that	the	xthA/nfo	mutant	is	decreased	in	mutation	frequency.	We	 propose	 that	 for	 the	 first	 peak	 of	 mutation	 frequency,	 repair	 of	 DNA	damage	 through	 base-excision	 repair	 enzymes	 leads	 to	 the	 formation	 of	 DNA	damage	 that	 can	 contribute	 to	 the	 fixation	 of	 mutations.	 More	 specifically,	 we	hypothesize	 that	 the	 action	of	 these	 repair	 enzymes	 lead	 to	DNA	double-stranded	breaks	(DSBs),	a	process	already	proposed	for	mutY	and	mutM	(Foti,	Devadoss	et	al.	2012),	which	are	repaired	in	a	mutagenic	way.	These	DSBs	should	turn	on	the	SOS	response,	and	specifically	up-regulate	translesion	polymerases,	which	then	convert	this	damage	to	G/C	deletions	(Illustration	3.5).	
	
Figure	3.5:	Model	for	mutagenesis	peak	at	50	μg/mL	nalidixic	acid.			In	conclusion,	our	data	indicate	that	nalidixic	acid	increases	mutation	rate	in	a	 concentration-dependent	 manner,	 with	 a	 narrow	 range	 of	 optimal-dosing	concentrations.	We	hypothesize	that	the	increase	in	mutation	rate	with	treatment	is	due	 to	 a	 breakdown	 in	 DNA	 repair	 leading	 to	 DSBs	 and	 error-prone	 repair	
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mechanisms.			
3.2.4	High	concentration	mutation	profile	As	described	above,	nalidixic	acid	induces	two	peaks	of	mutagenesis,	one	at	50	 μg/mL	 and	 one	 at	 approximately	 350	 μg/mL.	 Through	 the	 use	 of	 genetic	mutants,	we	hypothesized	the	first	peak,	which	is	highly	enriched	in	C/G	deletions,	to	 be	 caused	 by	 the	 action	 of	 translesion	 polymerases	 on	 damage	 formed	 by	glycosylases.	 Because	 of	 the	 rifampicin	 resistance	 data	 showing	 no	 high-concentration	peak,	we	hypothesized	that	the	high-concentration	peak	is	formed	by	a	different	mechanism	of	action.	To	probe	further	into	the	high-concentration	peak,	we	sequenced	the	cI-region	of	cells	 treated	at	high	concentrations	of	nalidixic	acid	(Figure	 3.6).	 Plotting	 the	 fold	 change	 in	mutation	 frequency,	 one	 can	 see	 that	 the	fold	change	for	each	mutation	is	between	100	and	2000	compared	to	untreated.	The	fold	change	at	50	μg/mL	on	the	other	hand	is	between	3	and	100	(Figure	3.6	a,b).		To	see	a	clearer	picture	of	which	mutations	are	up-regulated,	we	plotted	the	ratio	of	the	 percent	 of	 each	mutation	 (Figure	 3.6	 c,d).	We	 found	 that	 in	 the	 second	 peak	there	is	an	increase	in	transposons,	indels	and	long	deletions	compared	to	the	first	peak.	There	remains	an	increase	in	G/C	deletions,	but	to	a	lesser	extent	than	the	first	peak.	 This	 indicates	 that	 two	 different	 mechanisms	 are	 responsible	 for	 the	 two	increased	peaks	of	mutagenesis.	
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Figure	3.6:	Mutation	profile	at	 low	and	high	concentrations	of	nalidixic	acid.	The	first	two	figures	show	fold	change	in	mutation	frequency	for	specific	mutations	in	the	cI	region	of	the	genome	compared	to	un-treated	cells	for	cells	treated	with	a)	50	μg/mL	nalidixic	acid	for	90	minutes	and	b)	concentrations	between	250	and	400	μg/mL	which	displayed	high	TetR	frequencies.	The	last	two	figures	show	fold	change	in	 the	percent	 of	 specific	mutations	 compared	 to	un-treated	 cells	 for	 cells	 treated	
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with	a)	50	μg/mL	nalidixic	acid	for	90	minutes	and	b)	concentrations	between	250	and	400	μg/mL	which	displayed	high	TetR	frequencies.			 We	next	broke	down	the	mutation	data	for	each	peak	further	(Figure	3.7).	At	the	 lower	 peak,	 only	 1-basepair	 deletions	 are	 up-regulated	 compared	 to	 the	untreated	 samples	 (Figure	 3.7a).	 We	 found	 that	 transposons	 make	 up	 a	 large	proportion	of	mutations	in	the	high	peak,	compared	to	indels,	1-basepair	deletions	and	 point	 mutations	 (Figure	 3.7b).	 We	 then	 broke	 down	 the	 point	 mutations	 to	transition	 mutations—mutations	 between	 cytosine	 and	 thymine	 and	 between	adenine	and	guanine—and	transversions.	We	found	that	at	the	lower	concentration	peak,	 the	 point	mutations	 are	 primarily	made	 of	 transversions	 (Figure	 3.7c).	 This	fits	 with	 our	 observation	 that	 translesion	 polymerases	 are	 active	 at	 this	concentration	 because	 transversions	 generally	 require	 enzymatic	 activity.	 At	 the	higher	 concentration	 peak,	 point	 mutations	 are	 primarily	 made	 up	 of	 transitions	possibly	indicating	direct	damage	to	the	DNA	instead	of	enzymatic	mutagenesis.			 Because	of	the	differential	mutation	spectrum	at	the	low	peak	and	high	peak	of	 mutation	 frequency,	 we	 hypothesize	 that	 two	 vastly	 different	 mechanisms	 are	leading	to	mutagenesis	in	each	condition.	
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Figure	3.7:	 Breakdown	of	mutation	 ratios	 at	 low	 and	high	 concentrations	 of	
nalidixic	 acid.	 In	 the	 first	 two	figures	 the	mutations	have	been	broken	down	into	transposons,	 indels	 (insertions	 and	 deletions),	 1-basepair	 deletions	 and	 point	mutations	 in	 the	 cI	 region	 of	 the	 genome.	 They	 show	 the	 ratio	 of	 the	 percent	mutations	compared	to	un-treated	cells	for	cells	treated	with	a)	50	μg/mL	nalidixic	acid	 for	 90	 minutes	 and	 b)	 concentrations	 between	 250	 and	 400	 μg/mL	 which	displayed	high	TetR	 frequencies.	The	last	two	figures	group	the	point	mutations	as	transversions	or	transition	mutations.	They	show	the	ratio	of	the	percent	mutations	compared	to	un-treated	cells	for	cells	treated	with	a)	50	μg/mL	nalidixic	acid	for	90	minutes	and	b)	concentrations	between	250	and	400	μg/mL	which	displayed	high	TetR	frequencies.	
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3.3	CONCLUSION	
	 In	 this	 chapter	 I	 have	 explored	 stress-induced	 mutagenesis	 via	 quinolone	action.	 We	 found	 that	 nalidixic	 acid,	 a	 first-generation	 quinolone,	 has	 a	 dose-dependent	 mutation	 frequency	 with	 a	 peak	 at	 50	 μg/mL	 and	 a	 higher	 peak	 at	approximately	 250	 μg/mL.	 	 For	 these	 studies	we	 used	 an	 engineered	 Escherichia	coli	strain	with	a	constitutively-on	λcI	(Ind-)	cassette	that	represses	a	λpR	promoter	linked	to	a	tetA	resistance	gene	(Bjedov,	Dasgupta	et	al.	2007).	Using	this	strain,	we	could	measure	the	frequency	of	TetR	cells	by	plating	and	the	exact	mutations	causing	the	resistance	by	sequencing	the	cI-region.			 In	 the	 first	 peak	 of	 mutagenesis,	 we	 found	 a	 substantial	 increase	 in	 C/G	deletions.	We	further	found	that	by	removing	translesion	polymerases,	we	also	see	a	large	decrease	 in	 these	C/G	deletions.	Graham	Walker	proposed	template	slippage	as	a	mechanism	by	which	translesion	polymerases	such	as	DinB	can	create	deletions	on	homopolymeric	runs	(Foti,	Delucia	et	al.	2010).	The	sequence	where	we	saw	the	majority	of	C/G	deletions	within	the	cI	region	was	GATGGGGATGGG(G),	thus	making	template	slippage	a	likely	explanation.	We	found	it	surprising	that	we	did	not	see	an	equal	 increase	 in	 A/T	 deletions	 and	 hypothesize	 that	 damaged	 bases	 such	 as	oxidized	guanine	could	be	related	to	the	asymmetric	increase	in	deletions.			 We	next	found	that	mutants	that	reduce	double-stranded	breaks,	as	shown	in	Chapter	 2,	 also	 have	 a	 reduced	 mutation	 frequency.	 This	 implies	 that	 double-stranded	breaks	could	be	leading	to	increased	mutagenesis,	either	through	the	up-regulation	of	the	SOS	response	or	by	being	converted	to	mutations.	
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	 Finally,	 we	 found	 that	 the	 second	 peak	 for	mutagenesis	 has	 a	 significantly	distinct	 mutation	 spectrum	 compared	 to	 the	 first	 peak,	 implying	 a	 different	mechanism	 of	 stress-induced	 mutagenesis.	 The	 second	 peak	 corresponds	 to	concentrations	at	which	nalidixic	acid	begins	to	inhibit	RNA	and	protein	synthesis	as	well	 as	 deoxyribonucleic	 acid	 synthesis	 (Crumplin	 and	 Smith	1975),	 and	 the	drug	becomes	 bacteriostatic	 instead	 of	 bactericidal.	 Thus,	 although	 it	 is	 incredibly	surprising	 that	 there	 is	 such	 a	 strong	mutagenesis	 peak	 at	 high	 concentrations	 of	treatment,	it	is	not	unexpected	that	the	mechanism	by	which	mutagenesis	occurs	is	different.			 It	is	important	to	note	the	significance	of	the	finding	that	nalidixic	acid	has	a	dose-dependent	mutagenesis	 profile,	 which	 corresponds	 to	 its	 killing	 profile.	 The	small	range	of	concentration	where	mutagenesis	is	decreased	and	killing	increased	should	be	the	target	dosage	in	vivo.	Further,	drug	treatments	that	reduce	resistance,	such	 as	 drugs	 that	 can	 target	 glycosylases,	 should	 be	 considered	 as	 adjuvant	therapies.			
3.4	METHODS	
3.4.1	Strain	and	Media	conditions		 For	 these	 studies	 we	 used	 the	 MgCI	 strain,	 which	 is	 an	 engineered	Escherichia	 coli	 strain	with	a	 constitutively-on	λcI	 (Ind-)	 cassette	 that	 represses	a	λpR	promoter	 linked	 to	 a	 tetA	 resistance	gene	 (Bjedov,	Dasgupta	 et	 al.	 2007).	We	
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grew	 cells	 in	 Luria	 Broth	 (LB,	 Difco)	 at	 37°C.	We	 constructed	 knock-out	mutants	using	the	keio	collection	and	P1-transduction.		
3.4.2	Mutation	frequency	assay		 We	 assessed	 mutation	 frequency	 by	 studying	 tetracycline-resistance	 and	rifampicin-resistance.	We	grew	cells	overnight	and	diluted	them	1/10,000	in	1	mL	of	fresh	LB	in	a	14	mL	culture	tube	until	they	reached	an	OD	of	0.2.	We	then	treated	with	 varying	 concentrations	 of	 nalidixic	 acid	 (stock	 of	 10	 mg/mL	 diluted	 in	 DI	water).	After	90	minutes	of	treatment,	we	spun	500	μL	of	cells	down	in	Eppendorf	tubes	for	5	minutes	at	3500	rpm.	We	resuspended	these	cells	in	5	mL	total	of	fresh	LB	and	let	grow	overnight.	The	next	day	we	diluted	the	cultures	to	10-7.	We	plated	100	μL	of	 the	dilution	 that	gave	us	countable	colonies	on	un-treated	plates	and	a)	12.5	μg/mL	tetracycline	or	b)	200	μg/mL	rifampicin.	We	took	a	ratio	of	cells	on	the	selective	 plate	 vs	 cells	 on	 the	 non-selective	 plate	 to	 calculate	 the	 mutation	frequency.			
3.4.3	Mutation	spectrum	analysis		 To	 determine	 the	 mutation	 spectrum	 we	 used	 the	 same	 protocol	 as	 for	mutation	 frequency.	 After	 plating,	 we	 grew	 up	 one	 colony	 per	 plate,	 selected	randomly,	to	PCR	and	sequence	the	cI-region.	For	PCR	and	sequencing	we	used	the	primers:	 TCAGCCAAACGTCTCTTCAG	 (forward)	 and	
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GCCAATCCCCATGGCATCGAGTAAC	(reverse).	We	used	Clustal	omega	to	analyze	the	sequences	and	categorize	mutations.	For	each	condition	we	had	at	least	75	samples,	with	one	mutation	per	sample.	For	the	higher	mutation	peak,	the	concentration	for	the	peak	was	not	consistent.	Thus,	we	 treated	with	4	concentrations	between	250	μg/mL	 and	 400	 μg/mL	 and	 picked	 a	 colony	 from	 the	 plate	 that	 had	 increased	mutation	frequency.		 	
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CHAPTER	4:	TOLERANCE	
	
4.1	INTRODUCTION	
	 Antibiotics	are	the	main	tools	to	treat	infectious	diseases	caused	by	bacteria;	however,	effective	therapy	is	limited	by	the	ability	of	bacterial	populations	to	escape	lethal	drug	challenges.	The	evasion	of	antibiotic	stress	by	bacteria	can	be	separated	into	two	classes:	antibiotic	resistance,	mediated	by	genetically	encoded	factors,	and,	phenotypic	 antibiotic	 tolerance	 (Brauner,	 Fridman	 et	 al.	 2016).	 While	 bacterial	resistance	is	conferred	by	factors	such	as	efflux	pumps,	drug-inactivating	enzymes,	or	 drug-target	 mutations,	 the	 factors	 involved	 in	 phenotypic	 tolerance,	characterized	by	the	reversible	switching	of	a	cell	population	from	a	sensitive	state	to	 a	 tolerant	 one,	 are	 less	 well	 understood	 (Balaban,	 Merrin	 et	 al.	 2004,	 Bush,	Courvalin	et	al.	2011,	Balaban,	Gerdes	et	al.	2013).	This	form	of	antibiotic	treatment	failure	 is	 relevant	 to	 many	 infection	 types,	 including	 prosthetic	 implant-related	infections	associated	with	Staphylococcus	aureus	or	pulmonary	infections	associated	with	Mycobacterium	tuberculosis	(Lowy	1998,	Gomez	and	McKinney	2004,	Fauvart,	De	 Groote	 et	 al.	 2011).	 Recently,	 phenotypic	 tolerance	 has	 been	 identified	 as	 a	physiologic	 state	 that	 can	 promote	 the	 development	 of	 genetic	 resistance	 (Levin-Reisman,	 Ronin	 et	 al.	 2017),	 further	 underscoring	 the	 need	 to	 understand	 the	biological	basis	for	this	phenomenon.		 Many	 early	 investigations	 into	 phenotypic	 tolerance	 have	 found	 links	 to	intrinsic	 genetic	 factors,	 including	 toxin-antitoxin	 modules	 and	 stress	 response	
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regulators	(Moyed	and	Bertrand	1983,	Falla	and	Chopra	1998,	Spoering,	Vulic	et	al.	2006,	 Vazquez-Laslop,	 Lee	 et	 al.	 2006,	 Dorr,	 Vulic	 et	 al.	 2010).	 However,	 none	 of	these	factors	can	fully	account	for	the	variety	and	magnitude	of	observed	tolerance.	More	recently,	stress	responses	related	to	extrinsic	environmental	cues,	such	as	the	starvation-induced	stringent	response,	or	the	SOS	response,	have	been	identified	as	major	drivers	of	phenotypic	tolerance	(Dorr,	Lewis	et	al.	2009,	Wu,	Vulic	et	al.	2012,	Maisonneuve,	 Castro-Camargo	 et	 al.	 2013).	 This	 concept	 has	 suggested	 the	importance	of	the	bacterial	growth	environment	as	a	mitigating	factor	of	antibiotic	efficacy	(Harms,	Maisonneuve	et	al.	2016).	Consistent	with	this,	previously	reported	attempts	 to	 overcome	 antibiotic	 tolerance	 have	 focused	 on	metabolic	 stimulation	(Allison,	Brynildsen	et	al.	2011,	Meylan,	Porter	et	al.	2017).	In	these	studies,	tolerant	bacteria	were	 successfully	 sensitized	 to	 the	 aminoglycoside	 class	 of	 antibiotics	 by	stimulation	 of	 carbon	 catabolism,	 which	 drove	 the	 formation	 of	 a	 proton	 motive	force	and	facilitated	antibiotic	uptake.	Notably,	this	strategy	was	not	successful	with	other	classes	of	bactericidal	drugs.				 	Here,	 we	 investigate	 the	 mechanism	 of	 bacterial	 tolerance	 to	 quinolone	antibiotics	using	ciprofloxacin	(cipro)	as	the	model	drug.	Quinolone	lethality	derives	from	the	poisoning	of	 the	Type	 II	 topoisomerases,	DNA	gyrase	and	 topoisomerase	IV,	which	 is	 proposed	 to	 ultimately	 lead	 to	DNA	 fragmentation	 (Malik,	 Zhao	 et	 al.	2006).		Tolerance	to	quinolone	antibiotics	specifically	is	known	to	be	affected	by	the	density	of	 the	cell	population	(Drlica,	Malik	et	al.	2008).	Though	binding	to	type	II	topoisomerases	is	essential	for	quinolone-induced	death,	additional	factors,	such	as	
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byproducts	 of	 cellular	 respiration	 and	 metabolism	 can	 modulate	 the	 quinolones’	bactericidal	 properties	 (Drlica,	 Malik	 et	 al.	 2008,	 Dwyer,	 Belenky	 et	 al.	 2014,	Belenky,	 Ye	 et	 al.	 2015,	 Dwyer,	 Collins	 et	 al.	 2015).	 Recently,	 the	 formation	 of	tolerant	cells	to	quinolone	antibiotics	in	both	Escherichia	coli	and	S.	aureus	has	been	linked	to	the	ability	of	cells	to	produce	ATP	(Conlon,	Rowe	et	al.	2016,	Shan,	Brown	Gandt	 et	 al.	 2017),	 further	 underscoring	 an	 underlying	 metabolic	 basis	 of	 drug	efficacy.	We	find	that	metabolic	 limitations	are	the	major	driving	factor	in	density-dependent	quinolone	antibiotic	tolerance	and	identify	and	develop	a	strategy	to	re-sensitize	 metabolically	 limited,	 high	 density	 cultures	 of	 bacteria	 to	 quinolones,	which	 may	 have	 significant	 impact	 on	 the	 utility	 of	 this	 class	 of	 molecule	 in	 the	treatment	of	clinical	bacterial	infections.		
 
4.2	RESULTS	
4.2.2	Escherichia	coli	tolerance	to	ciprofloxacin	is	dependent	on	growth	phase.		 Cipro	 is	 currently	 the	 most	 widely	 used	 second-generation	 quinolone	(Goossens,	 Ferech	 et	 al.	 2007).	 With	 an	 MIC	 of	 8-10ng/ml	 in	 rich	 LB	 medium	targeting	E.	 coli	MG1655,	 cipro	 is	 one	 of	 the	most	 potent	 drugs	 of	 the	 quinolone	family.	 However,	 the	 lethal	 effect	 of	 cipro	 decreases	 as	 the	 bacterial	 population	grows	to	higher	cell	density	(Figure	4.1a–c).	While	the	bacterial	sensitivity	to	cipro	is	highest	during	exponential	growth	at	low	cell	density	(<1%	of	maximal	growth),	cells	 become	 more	 tolerant	 as	 soon	 as	 they	 reach	 10%	 of	 the	 maximal	 carrying	capacity	 in	 LB	 media.	 This	 density-dependent	 tolerance	 is	 characterized	 by	 the	
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inability	 of	 ciprofloxacin	 to	 kill	 a	 fraction	 of	 the	 cell	 population,	 even	with	 a	 dose	representing	 1000x	 the	MIC	 and	 a	 treatment	 time	 of	 24	 hours	 (Figure	 4.1b).	 The	fraction	of	 tolerant	cells,	also	called	persister	cells	 (Brauner,	Fridman	et	al.	2016),	significantly	 increases	 upon	 entry	 into	 the	 stationary	 phase	 (Figure	 4.1a–c)	 and	represents	10	to	100%	of	the	population	depending	on	the	drug	concentration	used	for	the	treatment.			 In	order	to	study	density-dependent	tolerance	to	cipro	in	depth,	we	tested	a	range	of	cultivation	conditions	to	optimize	our	experimental	approach.	We	treated	cells	with	1µg/ml	cipro	(100x	MIC)	as	this	concentration	achieved	maximal	killing	at	low	cell	density	and	moderate	killing	at	high	cell	density	(Figure	4.1b).	We	further	conducted	 our	 experiments	 in	 MOPS	 rich	 media	 to	 ensure	 that	 the	 density-dependent	 tolerance	observed	 in	LB	 is	 conserved	among	different	defined	growth	condition	(Figure	4.2a,b).	Consistent	with	previous	reports,	we	found	that	an	initial	dilution	 of	 1/10,000	 from	 overnight	 cultures	was	 necessary	 to	 avoid	 pre-existing	tolerant	 cells	 (Figure	 4.2c,d)	 (Keren,	 Kaldalu	 et	 al.	 2004,	 Brauner,	 Fridman	 et	 al.	2016).			 In	order	to	explore	what	factors	could	influence	the	cipro	density-dependent	tolerance	 we	 first	 looked	 at	 density-dependent	 susceptibility	 of	 a	 quinolone	hypersensitive	mutant	recB,	which	is	unable	to	repair	DNA	double-stranded	breaks.	Interestingly,	 we	 found	 that	 this	 mutant	 is	 still	 hypersensitive	 in	 the	 stationary	phase	 (Figure	 4.2e,f),	 suggesting	 that	 tolerance	 to	 cipro	 is	 not	 exclusively	 due	 to	reduced	 diffusion	 of	 the	 drug.	 We	 conclude	 that	 stationary	 phase	 cells	 are	 still	
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damaged	 by	 quinolones,	 but	 that	 the	 damage	 is	 not	 toxic	 in	 this	 condition.	 We	hypothesized	 that	 environmental	 constraints	 could	 be	 a	 factor	 in	 quinolone	tolerance	in	the	stationary	phase.		 To	 test	 this	 hypothesis,	 we	 looked	 at	 the	 expression	 of	 an	 unstable	 GFP	variant	 under	 the	 control	 of	 the	 ribosomal	 RNA	 promoter	 P1	 (P1rrnB)	(Maisonneuve,	 Castro-Camargo	 et	 al.	 2013,	 Mathieu,	 Fleurier	 et	 al.	 2016),	 the	activity	of	which	has	been	shown	to	correlate	with	the	overall	ability	of	the	cells	to	grow.	 We	 observed	 a	 gradual	 decrease	 in	 GFP	 expression	 as	 the	 cell	 population	increased	 followed	by	a	 steep	drop	 in	 fluorescence	emission	corresponding	 to	 the	entrance	 into	the	stationary	phase	(Figure	4.1d).	The	activity	of	P1rrnB	 correlated	with	the	large	increase	in	ciprofloxacin	tolerance	observed	in	stationary	phase	cells	(Figure	4.1c).	P1rrnB	activity	can	be	modulated	by	starvation	signaling	such	as	the	stringent	 response	or	alternatively	by	 the	depletion	of	 cellular	energy	stores	 from	nucleic	 acid	 triphosphate	 molecules	 (ATP,	 GTP)	 (Paul,	 Ross	 et	 al.	 2004).	 To	understand	which	 factor	 contributed	 to	 the	 observed	 decrease,	 we	 next	 explored	the	 contribution	 of	 the	 guanosine	 tetraphosphate-	 (ppGpp)	 mediated	 stringent	response	on	growth	dependent	tolerance	to	cipro.		
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Figure	4.1:	E.	coli	density-dependent	tolerance	to	ciprofloxacin.	a.	E.	coli	growth	in	LB	medium	over	time	(mean	±	SEM	n=7),	dashed	lines	represent	the	cell	density	sampling	 —	 green	 1%,	 red	 10%,	 and	 blue	 100%	 of	 the	 maximum	 density.	 b.	Ciprofloxacin	dose	 response	of	E.	coli	 (mean	±	SEM	n=3)	 from	culture	at	different	cell	density	—	green	1%,	red	10%,	and	blue	100%	of	 the	maximum	density—	the	dashed	line	highlights	the	concentration	of	1µg/ml,	which	is	used	in	the	future	sets	of	 experiments.	 c.	 Density-dependent	 tolerance	 to	 ciprofloxacin;	 each	 symbol	represents	a	different	biological	 replicate.	d.	Density-dependent	expression	of	GFP	by	 the	 P1rrnB	promoter;	 each	 symbol	 represents	 a	 different	 biological	 replicate.	 e.	Tolerance	to	ciprofloxacin	of	the	ppGpp0	mutant	in	stationary	phase	culture	(mean	±	
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SEM,	n=3,	*=P<0.05).	e.	Density-dependent	tolerance	to	ciprofloxacin	of	the	ppGpp0	mutant;	each	symbol	represents	a	different	biological	replicate.	c,f.	10-2*	shows	our	limit	of	detection.			 Phenotypic	tolerance	of	E.	coli	to	bactericidal	antibiotics,	including	cipro,	has	been	linked	with	the	stringent	response,	which	is	modulated	by	production	of	high	levels	of	ppGpp	by	the	enzymes	RelA	and	SpoT.	We	investigated	the	contribution	of	the	 E.	 coli	 stringent	 response	 to	 density-dependent	 tolerance	 to	 cipro	 using	 a	ppGpp0	strain	(Cashel	1975).		Consistent	with	previous	data	(Maisonneuve,	Castro-Camargo	et	al.	2013),	we	found	that	a	stationary	phase	relA	spoT	mutant	displayed	a	5.5-fold	reduction	 in	tolerant	cells	compared	to	wild	type	(P=0.017)	(Fig.	1E).	 	We	next	 assessed	 the	 accumulation	 of	 tolerant	 cells	 over	 varying	 cell	 densities	 in	 the	
relA	spoT	background.	Though	the	total	number	of	tolerant	cells	is	reduced	relative	to	 the	 wild	 type,	 the	 relA	 spoT	mutant	 still	 displays	 a	marked	 density-dependent	tolerance	phenotype	(Figure	4.1f).	We	measured	the	activity	of	the	P1rrnb	promoter	in	 the	 relA	 spoT	 background,	 and	 the	 effective	 drop	 in	 expression	 occurring	 in	stationary	 phase	 appeared	 to	 be	 independent	 of	 the	 production	 of	 ppGpp	 (Figure	4.2g).	 We	 conclude	 that	 the	 starvation	 itself,	 rather	 than	 the	 induction	 of	 the	stringent	response,	is	critical	for	density-dependent	tolerance	to	ciprofloxacin.			
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Figure	4.2:	E.	coli	density-dependent	tolerance	to	ciprofloxacin.	a.	Ciprofloxacin	dose	response	of	E.	coli	 in	MOPS	(mean	±	SEM	n=3)	 from	cultures	at	different	cell	density	 —	 green	 1%,	 red	 10%,	 and	 blue	 100%	 of	 the	 maximum	 density	 —	 the	dashed	line	highlights	the	concentration	of	1µg/ml	which	is	used	in	the	future	sets	of	 experiments.	 b.	 Density-dependent	 tolerance	 to	 ciprofloxacin	 in	 MOPS;	 each	symbol	 represents	a	different	biological	 replicate.	 c,d.	Dilution	effect	on	 tolerance;	cells	were	diluted	1/10	 to	1/10000	 fold	 from	 the	overnight	 culture,	 grown	 for	 an	
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hour	and	treated	with	1μg/mL	cipro	(c)	and	10μg/mL	cipro	(d)	for	24	hours.	e,f.	a	comparison	of	%	survival	of	WT	(blue)	and	ΔrecB	(white)	cells	treated	with	varying	concentrations	of	ciprofloxacin	at	stationary	phase	(e)	and	OD600~.2	(f).	g.	Density-dependent	 expression	 of	 GFP	 by	 the	 P1rrnB	promoter	 in	 the	 ppGpp0	mutant;	 each	symbol	 represents	 a	 different	 biological	 replicate.	 a–f.	 10-2*	 shows	 our	 limit	 of	detection.		
4.2.2	Both	carbon	and	oxygen	are	necessary	to	sensitize	stationary	phase	cells	
to	ciprofloxacin.	
	 We	next	sought	to	elucidate	the	factors	limiting	cell	death	after	cells	achieve	10%	maximal	growth	density.	To	have	a	greater	control	on	the	metabolic	inputs	in	the	culture,	we	elected	to	use	defined	MOPS	rich	media	for	these	experiments.	We	first	assessed	if	stationary	phase	carbon	depletion	was	responsible	for	the	density-dependent	 tolerance	 to	 ciprofloxacin.	 Addition	 of	 glucose	 to	 stationary	 phase	cultures	 restored	 minor	 ciprofloxacin	 activity.	 Sensitization	 to	 1µg/ml	 of	ciprofloxacin	by	glucose	was	dose	dependent	starting	at	0.4%	with	a	plateau	at	1%	glucose	(Figure	4.3a).	Because	oxygen	is	a	known	limiting	growth	factor	at	high	cell	density	 (Losen,	 Frolich	 et	 al.	 2004,	 Smirnova,	 Tyulenev	 et	 al.	 2017),	 and	 a	 known	parameter	 limiting	 quinolone	 sensitivity	 (Lewin,	 Morrissey	 et	 al.	 1991),	 we	 next	evaluated	 the	 effect	 of	 oxygenation	 on	 both	 the	 ciprofloxacin	 tolerance	 and	 the	sensitization	by	glucose.	To	do	so,	we	first	examined	stationary	phase	cell	sensitivity	in	 a	 static	 culture	 (Figure	 4.3a).	Notably,	while	 static	 cultures	 displayed	 the	 same	
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density-dependent	 tolerance	 to	 ciprofloxacin,	 the	 lack	 of	 continuous	 aeration	provided	 by	 shaking	 increased	 the	 tolerance	 above	 10%	 of	 maximal	 population	density	 (Figure	 4.3c).	 Importantly,	 we	 observed	 that	 static	 cultures	 receiving	 no	aeration	showed	no	sensitization	to	glucose	supplementation	(Figure	4.3a,e).	Thus	we	 identified	 that	 glucose	 supplementation	 can	 partially	 restore	 the	 activity	 of	quinolone	antibiotics,	but	only	under	conditions	of	aeration.			 To	 further	 explore	 this,	 we	 measured	 dissolved	 oxygen	 as	 a	 function	 of	growth	density	using	a	solid-state	fluorescence	detector	of	oxygen	sensitive	to	8ppb	under	static	growth	conditions	(Figure	4.3b).	We	found	that	steady-state	dissolved	oxygen	becomes	undetectable	at	220	min	of	growth,	corresponding	to	a	population	density	of	5e7	cells,	or	5%	of	maximal	growth.	Continuous	monitoring	of	stationary	phase	 cultures	 in	 static	 system	 showed	 that	 steady-state	 dissolved	 oxygen	 levels	remained	below	our	detection	limit	even	after	24h	of	static	incubation	(Figure	4.3b).			 To	confirm	that	bacterial	cells	were	responding	physiologically	to	changes	in	oxygen	tension	consistent	with	an	aerobic-to-anaerobic	transition,	we	measured	the	expression	of	 the	main	cytochrome	oxidase	and	 the	anaerobic	 fumarate	 reductase	gene,	 both	 of	 them	being	 differentially	 controlled	 by	 the	 transcriptional	 regulator	FNR	(Tseng,	Albrecht	et	al.	1996).	We	quantified	mRNA	level	of	cyoA	and	frdA	genes	by	 qPCR.	 We	 found	 expression	 patterns	 typical	 of	 aerobic-to-anaerobic	 shift,	demonstrating	progressive	cyoA	downregulation	and	increasing	frdA	expression	as	the	population	grew.	Thus	 in	 static	 culture,	 as	 cell	 density	 increases,	 the	bacterial	population	adapts	physiologically	by	re-organizing	its	electron	transport	chain	in	a	
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manner	consistent	with	reduced	oxygen	availability.				 To	 test	 the	hypothesis	 that	both	 carbon	and	oxygen	are	 significant	 limiting	factors	in	stationary	phase	killing	by	cipro,	we	evaluated	antibiotic	susceptibility	of	static	 cultures	 receiving	defined	oxygen	 supplementation.	We	provided	oxygen	by	bubbling	 filtered	air	 into	 the	media	at	 a	 calibrated	 rate	 to	maintain	a	 steady-state	oxygen	tension	of	5–6%	in	the	static	stationary	phase	cultures.	Consistent	with	our	hypothesis,	we	 found	 that	 stationary	phase	E.	 coli	was	highly	 susceptible	 to	 cipro	when	delivered	a	combination	of	glucose	and	oxygen,	while	addition	of	glucose	or	oxygen	alone	had	minimal	effect	(Figure	4.3e).	Interestingly,	under	this	specific	level	of	 glucose	 supplementation	 (0.4%),	 the	 degree	 of	 killing	 under	 static	 conditions	with	 defined	 oxygen	 supplementation	 exceeded	 killing	 found	 in	 the	 shaking	condition	 (Figure	 4.3a,e).	 Thus	 we	 identify	 that	 growth-dependent	 tolerance	 to	ciprofloxacin	 in	 the	 static	 condition	 is	mediated	by	 limitations	 in	both	carbon	and	oxygen,	 and	 supply	 of	 these	 two	 factors	 is	 sufficient	 to	 re-sensitize	 high-density	cultures	to	cipro.			 As	we	observed	increased	killing	in	the	oxygen-supplemented	static	cultures	relative	 to	shaking	cultures,	we	hypothesized	that	oxygen	may	be	a	 limiting	 factor	for	 even	 shaking	 stationary	 phase	 cultures.	 Due	 to	 the	 physical	 constraints	 of	 the	system,	we	were	not	able	 to	confidently	measure	dissolved-oxygen	 in	our	shaking	conditions	 with	 the	 oxygen	 probe.	 As	 a	 proxy	 for	 aero-anaerobic	 transition,	 we	evaluated	the	expression	levels	of	cyoA	and	frdA	in	shaking	cultures.	We	found	that	
cyoA	and	 frdA	expression	pattern	were	similar	 in	both	shaking	and	static	cultures,	
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suggesting	that	oxygen	tension	is	limiting	in	both	conditions	(Figure	4.3f).	
	
Figure	 4.3:	 E.	 coli	 dissolve	 oxygen	 concentration	 limits	 ciprofloxacin	
sensitivity	 at	 high	 cell	 density.	 a.	 Glucose-dependent	 sensitization	 to	 1µg/ml	 of	ciprofloxacin	 in	 stationary	 phase	 shaking	 (red	 bar)	 or	 static	 (blue	 bar)	 culture.	 b.	Evolution	of	dissolved	oxygen	concentration	 (left	 axis)	 and	growth	 in	E.	coli	static	culture	(right	axis	mean	±	SEM,	n=5).	For	dissolved	oxygen	each	symbol	represents	a	different	replicate.	c.	Density-dependent	tolerance	to	ciprofloxacin	in	E.	coli	static	culture;	each	symbol	represents	a	different	biological	replicate.		d.	Measurement	of	the	frdA	and	cyoA	mRNA	representing	the	aero-anaerobic	transition	in	static	culture	(mean	±	SEM,	n=3).	e.	Aeration-dependent	sensitization	of	E.	coli	stationary	culture	
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by	glucose	 to	1µg/ml	of	 ciprofloxacin.	 f.	Measurement	of	 the	 frdA	and	cyoA	mRNA	representing	 the	aero-anaerobic	 transition	 in	 aerated	 culture.	 a,e.	Data	 represents	the	mean	±	SEM	n=3	of	 the	percent	survival	 compared	 to	ciprofloxacin	untreated;	10-4*	shows	our	limit	of	detection.			
4.2.3	Fumarate	can	substitute	oxygen	as	an	electron	acceptor	to	sensitize	cells	
to	ciprofloxacin.		 The	 E.	 coli	 respiration	 system	 is	 very	 versatile	 and	 the	 quinol	 pool	 can	transfer	electrons	to	substrates	other	than	oxygen	(Unden	and	Bongaerts	1997).	We	asked	if	anaerobic	respiration	using	an	alternative	electron	acceptor	could	also	lead	to	glucose-dependent	 sensitization	 to	 cipro	 in	 stationary	phase.	We	 tested	nitrate,	DMSO	and	 fumarate	as	alternative	electron	acceptors	 in	aerated	MOPS	rich	media	(Figure	 4.4a).	While	 none	 of	 these	 electron	 acceptors	 alone	was	 able	 to	 sensitize	cells	to	ciprofloxacin,	we	found	that	in	combination	with	glucose,	fumarate	was	able	to	 synergistically	 sensitize	 stationary	 phase	 cells	 to	 1µg/ml	 cipro	 (Figure	 4.4a).	Increasing	glucose	over	0.2%	did	not	enhance	killing	in	conjunction	with	fumarate	(Figure	4.5a),	 indicating	again	 that	 carbon	sources	availability	 is	 required,	but	not	strictly	limiting	for	density-dependent	tolerance	to	cipro.			 We	next	 assessed	 the	dose-dependent	 relationship	of	 cipro	 sensitization	 to	the	 combination	 of	 glucose	 and	 fumarate.	 While	 sensitization	 was	 limited	 to	concentrations	 above	 500	 ng/ml	 of	 cipro	 for	 the	MOPS	 rich	media	 (Figure	 4.4b),	stationary	 phase	 cells	 grown	 in	 LB	 and	 supplemented	with	 glucose	 and	 fumarate	
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were	killed	by	cipro	at	concentrations	as	low	as	50ng/ml	(Figure	4.4c).		
	
Figure	4.4:	Fumarate	respiration-dependent	sensitization	 to	ciprofloxacin	by	
glucose.	 	 a.	 Alternative	 electron	 acceptors	 synergize	 glucose	 sensitization	 to	1µg/mL	 of	 ciprofloxacin	 in	 MOPS	 rich	 media.	 b.	 Glucose-fumarate	 (0.2%–0.2%)	synergy	across	ciprofloxacin	concentration	in	MOPS	rich	media	(mean	±	SEM,	n=3).	c.	Glucose-fumarate	(0.2%–0.2%)	synergy	across	ciprofloxacin	concentration	in	LB	media	 (mean	 ±	 SEM,	 n=3).	 d.	 The	 glucose-fumarate	 synergy	 depends	 on	 the	fumarate	 reductase	 activity.	 b,c,d.	 10-4*	 shows	 our	 limit	 of	 detection.	 e,f	 Glucose-fumarate	sensitization	to	different	concentrations	of	gentamycin	(e)	and	ampicillin	(f).		
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	 As	 our	 data	 suggested	 that	 cellular	 respiration	 was	 a	 limiting	 factor	 for	sensitization	by	glucose,	we	next	directly	tested	this	using	a	knockout	strategy.	We	previously	found	that	the	fumarate	reductase	gene	was	significantly	upregulated	in	stationary	phase	E.	coli,	and	that	providing	fumarate,	the	substrate	for	this	enzyme,	sensitized	the	cells	to	cipro.	We	thus	tested	a	mutant	lacking	the	catalytic	subunit	of	the	fumarate	reductase,	FrdA.	We	found	that	the	frdA	knockout	mutant	was	not	able	to	be	sensitized	to	ciprofloxacin	killing	by	the	combination	of	glucose	and	fumarate,	suggesting	a	direct	role	of	alternative	respiration	 through	 fumarate	reduction	as	a	key	 factor	 in	 sensitizing	 cells	 to	 ciprofloxacin	 (Figure	 4.4d	 and	 Figure	 4.5).	Complementation	 of	 the	 frdA	mutant	 using	 a	 plasmid	 expressing	 the	 frdA	 gene	under	the	control	of	the	native	promoter	restored	sensitization	to	ciprofloxacin	by	glucose	and	fumarate	supplementation.				 We	 next	 sought	 to	 better	 understand	 how	 the	 enzymatic	 reduction	 of	fumarate	 is	 leading	 to	 cell	 death	 when	 cells	 are	 exposed	 to	 ciprofloxacin.	 We	hypothesized	 that	 the	 addition	 of	 fumarate	 was	 sensitizing	 cells	 by	 increasing	cellular	 respiration	 as	 a	 component	 of	 overall	 cellular	metabolism.	 An	 alternative	hypothesis	 was	 that	 the	 addition	 of	 glucose	 and	 fumarate	 restored	 cell	 growth,	leading	 to	 sensitization.	 Although	 we	 did	 not	 observe	 a	 significant	 increase	 in	CFU/mL	 after	 the	 addition	 of	 glucose	 and	 fumarate,	 we	 wanted	 to	 use	 a	 more	sensitive	method	to	differentiate	cellular	respiration	and	cell	growth.	To	assess	this,	we	 asked	 whether	 glucose	 and	 fumarate	 supplementation	 could	 sensitize	stationary-phase	cells	to	ampicillin,	a	β-lactam	antibiotic	which	requires	cell	growth	
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and	division	for	killing,	or	gentamicin,	which	requires	an	active	metabolism	and	the	generation	 of	 a	 proton	 motive	 force	 for	 drug	 uptake.	 Confirming	 our	 original	hypothesis,	we	 found	that	glucose-fumarate	supplementation	sensitized	stationary	phase	E.	coli	to	gentamicin,	however	even	high	concentrations	of	ampicillin	did	not	kill,	suggesting	that	the	metabolite	addition	was	not	inducing	significant	cell	growth	(Figure	4.4e,f).	 	 	
	
Figure	4.5:	Glucose-fumarate	potentiation.	a.	%	survival	of	stationary	phase	cells	treated	with	1µg/mL	ciprofloxacin	at	varying	concentrations	of	added	glucose	and	0.4%	added	fumarate	(red)	or	no	fumarate	(blue).	b.	%	survival	of	stationary	phase	cells	 treated	 with	 1µg/mL	 ciprofloxacin	 and	 varying	 concentrations	 of	 added	glucose	in	the	ΔfrdA	background	(red)	and	WT	background	(blue).	
	
		
70	
4.2.4	 Carbon	 source	 and	 electron	 acceptor	 availability	 limits	 ciprofloxacin	
activity	in	Staphylococcus	aureus	and	Mycobacterium	smegmatis.		 Having	 defined	 the	mechanistic	 context	 for	 density-dependent	 tolerance	 to	cipro	 in	 a	 Gram-negative	 organism,	 we	 tested	 whether	 our	 findings	 were	 more	generalizable	 to	 two	 additional	 clinically	 relevant	 pathogens,	 S.	 aureus	 (MIC:	250µg/ml)	 and	 M.	 smegmatis	 (MIC:	 500ng/ml).	 Though	 cipro	 alone	 was	 not	 as	potent	for	treating	S.	aureus	and	M.	smegmatis	in	exponentially	growing	cultures	as	for	E.	coli,	higher	doses	could	successfully	reduce	the	number	of	viable	cells	below	the	limit	of	detection	for	both	strains	(Figure	4.6a,b).	Similar	to	E.	coli,	S.	aureus	and	
M.	smegmatis	exhibit	marked	density-dependent	tolerance	to	cipro	upon	entry	into	stationary	phase	(Figure	4.6a,b).			 Because	 the	 M.	 smegmatis	 genome	 includes	 several	 putative	 fumarate	reductase	 enzymes	 (Caspi,	 Billington	 et	 al.	 2016)	 we	 tried	 to	 sensitize	 aerated	stationary	phase	cultures	to	cipro	by	using	a	combination	of	glucose	and	fumarate.	We	found	that	while	0.4%	fumarate	or	0.4%	glucose	alone	could	sensitize	cultures	weakly,	 the	 combination	 of	 both	 compounds	 strongly	 sensitized	 M.	 smegmatis	stationary	 phase	 cultures.	 S.	 aureus	 is	 not	 able	 to	 use	 fumarate	 as	 an	 alternative	electron	acceptor	(Fuchs,	Pane-Farre	et	al.	2007,	Caspi,	Billington	et	al.	2016).	Thus,	we	 tried	 sensitizing	 S.	 aureus	 stationary	 cultures	 to	 cipro	 by	 the	 combination	 of	oxygen	and	glucose.	As	observed	 in	stationary	phase	cultures	of	E.	coli,	the	steady	state	dissolved	oxygen	concentration	 in	 stationary	phase	 statically	grown	cultures	of	S.	aureus	was	undetectable.	While	the	addition	of	glucose	or	bubbling	had	either	
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no	effect	or	only	a	very	limited	one	on	cipro	tolerance;	the	addition	of	0.4%	glucose	together	with	bubbling	 sensitized	 the	S.	aureus	static	 culture	 to	5	 and	10µg/ml	of	cipro	 (Figure	 4.6c,d).	 Thus	 we	 identify	 that	 the	 stimulation	 of	 metabolism	specifically	 at	 the	 level	 of	 cellular	 respiration	 is	 a	 broadly	 active	 approach	 to	sensitizing	a	range	of	non-dividing	pathogens	to	cipro.		
															 	
Figure	 4.6:	 Sensitization	 to	 ciprofloxacin	 in	 clinical	 relevant	 pathogens. A.	Density-dependent	tolerance	to	ciprofloxacin	in	M.	smegmatis;	blue	line	corresponds	to	 stationary	 phase	 cells	 and	 red	 line	 corresponds	 to	 cells	 treated	 at	 OD600~	 .2	maximal	 density.	B.	 Density	 dependent	 tolerance	 to	 ciprofloxacin	 in	 S.	 aureus.	C.	
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Glucose-fumarate	sensitization	of	stationary	M.	smegmatis	phase	to	ciprofloxacin.	D.	Aeration-dependent	glucose	sensitization	of	S.	aureus	stationary	phase.	10-4*	shows	our	limit	of	detection.  
4.3	DISCUSSION	
	 Density-dependent	tolerance	to	quinolone	antibiotics	is	a	well-characterized	phenotype	 without	 a	 well-defined	 mechanism.	 In	 this	 study,	 we	 concluded	 that	limitations	to	metabolic	activity,	and	not	the	cell	response	to	starvation,	are	the	key	factor	 blocking	 ciprofloxacin	 activity	 under	 high	 cell-density	 conditions.	 While	carbon	source	availability	is	necessary,	we	found	that	carbon	oxidation	alone	is	not	a	sufficient	 factor	to	stimulate	ciprofloxacin	activity,	and	the	additional	availability	of	a	suitable	terminal	electron	acceptor	is	critical	to	regenerate	the	lethal	efficacy	of	ciprofloxacin	 in	 tolerant	cells.	Using	this	conceptual	 framework	we	found	a	simple	strategy	 to	 stimulate	 the	 activity	 of	 ciprofloxacin	 against	 a	 range	 of	 clinically	relevant	 bacterial	 pathogens	 at	 high	 densities.	 To	 our	 knowledge,	 this	 is	 the	 first	work	 showing	 metabolite-enabled	 potentiation	 of	 ciprofloxacin	 to	 high-density	cultures.		 An	 emerging	 model	 for	 bacterial	 tolerance	 to	 antibiotics	 has	 focused	 on	physiologic	 adaptation	 to	 starvation,	 as	 mediated	 by	 the	 stringent	 response	(Nguyen,	 Joshi-Datar	 et	 al.	 2011,	 Amato,	Orman	 et	 al.	 2013,	Maisonneuve,	 Castro-Camargo	 et	 al.	 2013,	Meylan,	 Porter	 et	 al.	 2017).	A	 key	 finding	 from	our	work,	 in	particular	using	a	ppGpp0	strain,	is	that	we	propose	that	starvation	itself	rather	than	
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the	cellular	adaptation	to	starvation	is	the	major	driving	force	in	density-dependent	tolerance.	When	 assessing	 the	 literature	 on	 antibiotic	 tolerance,	 it	 is	 important	 to	make	 a	 distinction	 between	 induced	 and	 stochastic	 tolerant/persister	 cells	(Michiels,	 Van	 den	 Bergh	 et	 al.	 2016)	 (also	 called	 Type	 I	 and	 Type	 II	 persisters	(Levin-Reisman	 and	 Balaban	 2016)),	 the	 former	 of	which	we	 have	 referred	 to	 as	density-dependent	tolerance.	We	believed	that	the	cells	remaining	after	the	addition	of	 glucose	 and	 fumarate	 represent	 Type	 II	 persisters,	 and	 cannot	 be	 simply	metabolically	sensitized	to	drugs.			 Another	 key	 conclusion	 from	 this	 study	 was	 that	 the	 supply	 of	 material	required	 for	 respiration	 is	 enough	 to	 sensitize	 cells	 to	 cipro.	 It	 is	 known	 that	topoisomerase	activity	is	an	ATP-dependent	process,	and	that	stationary	phase	cells	require	topoisomerases	to	recover	supercoiling	(Gutierrez-Estrada,	Ramirez-Santos	et	 al.	 2014).	 Furthermore,	 increased	 cellular	 respiration	 has	 been	 implicated	 in	antibiotic-mediated	 death	 through	 downstream	 processes	 (Lobritz,	 Belenky	 et	 al.	2015).	We	hypothesize	that	the	up-regulation	of	metabolism	through	the	addition	of	a	 carbon	 source	 and	 electron	 acceptor	 affects	 both	 drug-target	 interactions	 and	downstream	processes	to	sensitize	cells	to	quinolones.		 While	 previous	 studies	 of	 starvation	models	 have	 focused	 on	 the	 study	 of	available	carbon	and	nitrogen	nutrients	in	the	media	(Allison,	Brynildsen	et	al.	2011,	Nguyen,	 Joshi-Datar	 et	 al.	 2011,	 Amato,	 Orman	 et	 al.	 2013,	 Maisonneuve,	 Castro-Camargo	et	al.	2013,	Amato	and	Brynildsen	2014,	Harms,	Maisonneuve	et	al.	2016,	Meylan,	 Porter	 et	 al.	 2017,	 Shan,	 Brown	 Gandt	 et	 al.	 2017),	 we	 found	 that	 high-
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density	static	cultures	quickly	utilize	the	available	dissolved	oxygen,	rendering	this	molecule	limiting	in	the	metabolic	process	of	cellular	respiration.	By	coupling	these	measurements	 to	 gene	 expression	 level	 data	 that	 typifies	 the	 aero-anaerobic	transition,	 cyoA	 and	 frdA,	we	 found	 that	 oxygen	 becomes	 limiting	 in	 both	 aerated	and	static	cultures	before	entry	into	the	stationary	phase.	In	our	aerated	cultivation	system	 with	 the	 model	 bacteria	 E.	 coli	 we	 started	 to	 detect	 an	 increase	 in	ciprofloxacin	 tolerance	when	 the	population	 reached	1e8	cells	per	ml	of	LB	media.	This	 density	 corresponded	 to	 an	 OD600	 of	 0.3	 and	 to	 approximately	 10%	 of	 the	maximal	 carrying	 capacity,	 which	 corresponds	 to	 a	 well-described	 change	 in	 the	growth	status	of	cells	in	LB	media	(Sezonov,	Joseleau-Petit	et	al.	2007).	In	the	static	condition,	 we	 found	 that	 a	 culture	 with	 1e8	 cells	 per	 ml	 is	 enough	 to	 deplete	dissolved	oxygen	in	1	minute.	These	findings,	combined	with	the	knowledge	that	the	bactericidal	 activity	 of	 drugs	 such	 as	 quinolones	 is	 very	 sensitive	 to	 the	 aero-anaerobic	 transition	 (Lewin,	 Morrissey	 et	 al.	 1991,	 Malik,	 Hussain	 et	 al.	 2007),	suggest	the	importance	of	the	experimental	growth	condition	(treatment	OD600)	as	well	 as	 sample	handling	 in	assessments	of	 antibiotic	 sensitivity.	We	question	how	the	 variety	 of	 growth	 conditions	 applied	 in	 laboratories	 around	 the	 world	 can	impact	conclusions	made	in	the	field	of	antimicrobial	research.	We	further	question	how	 genetic	 mutants,	 which	 can	 deplete	 medium	 resources	 such	 as	 electron	acceptors	 differentially	 compared	 to	 their	 WT	 ancestor,	 are	 used	 to	 explore	 the	impact	 of	 metabolism	 on	 antibacterial	 drug	 activity,	 and	 we	 propose	 that	 the	percent	maximal	carrying	capacity	should	be	considered	when	making	comparisons	
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between	genetic	mutants	and	their	ancestor	strain.			 Although	 antibiotic	 tolerance	 has	 been	 previously	 implicated	 in	 recurring	and	 chronic	 infections	 (Fauvart,	 De	 Groote	 et	 al.	 2011),	 it	 is	 now	 also	 being	appreciated	as	an	important	factor	that	could	favor	the	appearance	and	the	spread	of	 resistant	 bacteria	 (Levin-Reisman,	 Ronin	 et	 al.	 2017).	 The	 antibacterial	 drugs	from	 the	 quinolone	 family	 are	 a	 significant	 component	 of	 the	 arsenal	 against	bacterial	infectious	diseases.	However,	a	single	nucleotide	polymorphism	within	one	of	 the	gyrase	subunits	can	 increase	 the	MIC	of	quinolones	by	orders	of	magnitude	(Levy,	Sharma	et	al.	2004),	rendering	the	drug	treatment	useless.	It	is	important	to	note	that	tolerance	displayed	by	high	cell	density	population	could	also	be	subject	to	selection	 through	 adaptive	 mutagenesis	 (Laureti,	 Matic	 et	 al.	 2013).	 Thus	 it	 is	critical	that	we	understand	the	mechanistic	underpinnings	of	antibiotic	tolerance,	so	that	 rational	 approaches	 to	 deployment	 of	 the	 antibiotic	 arsenal	 can	 be	 achieved	(Smith	and	Romesberg	2007).		 				
4.4	METHODS	
4.4.1	Experimental	Model	The	 strains	 used	 for	 this	 study	 were	 E.	 coli	 K12	 strain	 MG1655,	 S.	 aureus	 strain	ATCC	25923	and	M.	smegmatis	strain	MC2	155.	E.	coli	MG1655	was	provided	by	the	
E.	 coli	 Genetic	 Stock	 Center	 database	 and	 sequenced	 by	 Blattner	 et	 al.	 (Blattner,	Plunkett	et	al.	1997).	S.	aureus	and	M.	 smegmatis	were	provided	by	ATCC	 .	E.	 coli	
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and	 S.	 aureus	were	 grown	 in	 Luria	 Broth	 (LB,	 Difco)	medium	 and	MOPS	 EZ	 Rich	(MOPS,	 Teknova)	 medium	 supplemented	 with	 0.2%	 glucose.	 M.	 smegmatis	 was	grown	 in	Middlebrook	7H9	 supplemented	with	 .05%	oleic	 acid,	 2%	dextrose,	 and	.004%	catalase	(OADC).	All	cells	were	grown	at	37°C10.			
4.4.2	Chemical	preparation	Antibiotics	 stock	 solutions	 were	 made	 as	 follows:	 ciprofloxacin	 was	 dissolved	 to	10mg/mL	 in	 0.1M	 NaOH,	 gentamicin	 was	 dissolved	 to	 10mg/mL	 in	 water	 and	ampicillin	was	 dissolved	 to	 10mg/mL	 in	water.	 All	metabolites	were	 dissolved	 in	water	to	the	following	stock	solutions:	40%	glucose,	20%	fumarate,	1M	potassium	nitrate.		
4.4.3	Knockout	construction	
E.	coli	genetic	knockouts	ΔrecB	and	ΔfrdA	and	were	constructed	by	P1	transduction	from	 the	 Keio	 collection.	 Knockout	 strains	 were	 checked	 for	 accuracy	 by	 PCR	amplification	and	gel	electrophoresis.			
4.4.4	Plasmid	construction	The	pZE21	backbone	was	used	 for	construction	of	all	plasmids	(Table	1).	The	kan	cassette	 in	 the	 pZE21	was	 replaced	with	 a	 the	 CmR	 cassette	 flanked	 by	 FRT	 sites	from	 the	 pKD3	 vector.	 The	 frdA	 promoter	 replaced	 the	 tet	 promoter	 through	 the	
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xhoI	and	kpnI	cut	sites.	The	mcherry	gene	was	replaced	by	frdA	using	the	kpnI	and	hindIII	cut	sites.	These	plasmids	were	selected	by	35	μg/mL	chloramphenicol.	The	p1-rrnb-gfp	 plasmid	 was	 made	 directly	 from	 the	 pZE21-mcherry	 backbone	 and	selected	 on	 50	 μg/mL	 kanamycin.	 Plasmids	 were	 transformed	 into	 background	strains	using	CaCl2	transformation.			
4.4.5	Potentiation	assays	Cells	 were	 grown	 for	 24	 hours	 in	 either	 a)	 a	 non-baffled	 flask	 overnight	 in	 the	shaking	incubator,	37°C,	300	rpm	(shaking	condition)	or	b)	in	30	mLs	in	a	100	mL	bottle	in	a	37°C	water	bath	(static	condition).	For	the	shaking	condition,	the	volume	of	culture	was	set	a	tenth	of	the	flask	volume.	For	potentiation	via	metabolites,	one	mL	 of	 culture	 was	 allocated	 to	 14	 mL	 culture	 tubes	 and	 treated	 with	 varying	concentrations	 of	 ciprofloxacin,	 sugars	 and	 electron	 acceptors.	 After	 24	 hours	 of	treatment,	100μL	of	 cells	were	spun	down	 for	5	minutes	at	3500rpm	 in	a	96-well	plate.	 	Cells	were	 resuspended	 in	PBS	and	serially	diluted	 in	PBS	by	10-fold	up	 to	107-fold.	E.	coli,	S.	aureus	were	spotted	on	LB	Agar	(Difco)	plates;	M.	smegmatis	was	spotted	on	7H10	+	OADC	supplement	plates.	The	plates	were	incubated	at	37°C	and	colonies	 were	 counted,	 reported	 as	 colony-forming	 units	 per	 mL	 (CFU/mL).	 For	potentiation	with	oxygen,	air	was	bubbled	into	cells	grown	in	the	static	condition	for	12	 hours	 with	 or	 without	 glucose.	 These	 cells	 were	 then	 spun	 down	 and	resuspended	in	PBS,	serially	diluted	and	plated	on	LB	Agar	plates.	
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4.4.6	Density-Tolerance	assay	An	 overnight	 culture	 of	E.	 coli	 was	 diluted	 1/10,000	 in	MOPS	 or	 LB	 in	 a)	 a	 non-baffled	flask	in	the	shaking	incubator,	37°C,	300	rpm	(shaking	condition)	or	b)	in	30	mLs	 in	 a	 100	mL	 bottle	 in	 a	 37°C	water	 bath	 (static	 condition).	 At	 varying	 time-points	throughout	growth,	1	mL	of	cells	were	moved	to	a	culture	tube	and	treated	with	1	μg/mL	ciprofloxacin;	 the	 tubes	were	placed	 in	 shaking	or	 static	 conditions	respectively.	At	each	time-point,	cells	were	also	serially	diluted	in	PBS	and	plated	on	LB	Agar	plates	to	determine	the	CFU/mL	at	the	time	of	treatment.	Time	points	were	taken	until	cells	reached	maximum	carrying	capacity.	After	24	hours	of	 treatment,	100μL	of	cells	from	each	tube	was	spun	down	and	re-suspended	in	PBS	on	a	96-well	plate.	Cells	were	then	serially	diluted	and	plated	on	LB	Agar	plates.	The	CFU/mL	at	treatment	 was	 normalized	 by	 the	 CFU/mL	 of	 stationary	 phase	 cells	 (%max	CFU/mL).		
4.4.7	Dilution	assay	An	 overnight	 culture	 of	 E.	 coli	was	 diluted	 1/10,	 1/100,	 1/1000,	 and	 1/10000	 in	non-baffled	 flasks.	 The	 cultures	were	 grown	 for	 1	 hour	 and	 treated	with	 either	 1	μg/mL	or	10μg/mL	cipro	for	24	hours.	Cells	were	spun	down	and	re-suspended	in	fresh	LB,	diluted	and	plated	on	LB	agar	plates	to	determine	CFU/mL.		
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4.4.8	Fluorescent	reporter	measurements	Fluorescence	 was	 measured	 by	 a	 SpectraMax	 M3	 Microplate	 Reader	spectrophotometer	(Molecular	Devices).	For	P1rrnb-gfp	signal,	an	overnight	culture	of	 cells	was	 diluted	 1/10,000	 in	MOPS	 or	 LB	 containing	 50	 μg/mL	 kanamycin.	 At	appropriate	 time	points	during	growth,	300	μL	of	cells	were	moved	to	a	black	96-well	 plate	 with	 clear	 bottom.	 The	 GFP	 signal	 was	 read	 on	 the	 plate	 reader	 at	 an	emission/excitation	of	488/510	and	PMT	of	20.	At	each	time	point,	cells	were	also	serially	diluted	and	plated	for	CFU/mL	determination.			
4.4.9	Oxygen	probe	measurements	Dissolved	 oxygen	 in	 the	 media	 was	 measured	 using	 a	 Mettler	 Toledo	 InPro	 O2	sensor,	68601.		The	probe	was	kept	in	a	static	culture	of	cells	in	a	water	bath	and	the	probe	measured	the	percent	of	dissolved	oxygen	every	five	minutes.			
4.4.10	QPCR	Bacterial	pellets	were	collected	and	stored	using	RNAprotect	(Qiagen)	according	to	manufacturers	 instructions	and	RNA	was	 isolated	using	 the	RNeasy	RNA	 isolation	kit	(Qiagen).	RNA	was	reverse	transcribed	with	random	hexamers	using	the	Verso	RT	kit	(Thermo	Fisher	Scientific).	Relative	gene	expression	was	determined	using	SYBR	Green	1	based	real	time	PCR	(Roche).	Concentrations	were	calculated	from	the	linear	standard	curve	and	all	transcripts	were	normalized	to	zw	
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Table	1:	Methods	details	REAGENT	or	RESOURCE	 SOURCE	 IDENTIFIER	Bacterial	and	Virus	Strains		Escherichia	coli	MG1655	 E.	coli	Genetic	Stock	Center	 CGSC#	6300	Staphylococcus	aureus		 ATCC	 25923	Mycobacterium	smegmatis	MC2	155	 ATCC	 700084	MG1655	ΔfrdA	 this	paper	 	MG1655	ΔrelAΔspoT	 (Mathieu,	Fleurier	et	al.	2016)	 	Chemicals,	Peptides,	and	Recombinant	Proteins	LB	Broth	 Difco	 Lot	#	5202513	Critical	Commercial	Assays		 	 	Oligonucleotides	cyoA	forward	primer	for	QPCR:	GGTACTTCCAGGCGAAACCA	 This	paper	 N/A	cyoA	reverse	primer	for	QPCR:	TTGGTCTGGAGCAACGTTCA	 This	paper	 N/A	frdA	forward	primer	for	QPCR:	TACGTTGACGCTACCATCCG	 This	paper	 N/A	frdA	reverse	primer	for	QPCR:	TATTTCGTCCACCACTGCCC	 This	paper	 N/A	zwf	forward	primer	for	QPCR:	TGCCGCTTTATCCCAGTCAG	 This	paper	 N/A	zwf	reverse	primer	for	QPCR:	GCGTCGTAAATTGCTGCCTT	 This	paper	 N/A	Primer	to	clone	frdA	promoter	into	pZE	backbone,	forward:	GATA	CTCGAG	ATCAAACAGCGGTGGG	 This	paper	 N/A	Primer	to	clone	frdA	promoter	into	pZE	backbone,	reverse:	GTAT	GAATTC	GACATTCCTCCAGATTGT	 This	paper	 N/A	Primer	to	clone	frdA	gene	into	pZE	backbone,	forward:		ctga	GGTACCgtgCAAACCTTTCAAGC	 This	paper	 N/A	Primer	to	clone	frdA	gene	into	pZE	backbone,	reverse:		gtca	ggatcc	tcaGCCATTCGCCT	 This	paper	 N/A	
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frdA	forward	sequencing:		GTGCAAACCTTTCAAGC	 This	paper	 N/A	frdA	reverse	sequencing:		TCAGCCATTCGCCTTC	 This	paper	 N/A frdA	promoter	forward	sequencing:		ATCAAACAGCGGTGGG	 This	paper	 N/A	Recombinant	DNA	 	 	Plasmid:	P1rrnB-GFP-kan	 (Mathieu,	Fleurier	et	al.	2016)	 	Plasmid:	PfrdA::frdA-cat	 This	paper	 	
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